<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Life Sciences Law - KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</title>
	<atom:link href="https://www.kg-legal.eu/info/tag/life-sciences-law/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.kg-legal.eu/info/tag/life-sciences-law/</link>
	<description>KIELTYKA GLADKOWSKI LEGAL &#124; CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</description>
	<lastBuildDate>Mon, 16 Nov 2026 16:32:17 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
	<item>
		<title>“For Research Use Only” Is Not a Legal Shieldgg</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/for-research-use-only-is-not-a-legal-shieldgg/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/for-research-use-only-is-not-a-legal-shieldgg/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 16:32:17 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[active pharmaceutical ingredients]]></category>
		<category><![CDATA[advertising compliance]]></category>
		<category><![CDATA[brand protection]]></category>
		<category><![CDATA[CLP]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[cross-border e-commerce]]></category>
		<category><![CDATA[Digital Services Act]]></category>
		<category><![CDATA[DSA compliance]]></category>
		<category><![CDATA[falsified medicines]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[influencer marketing]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[laboratory suppliers]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[medicinal product classification]]></category>
		<category><![CDATA[medicinal products by function]]></category>
		<category><![CDATA[medicinal products by presentation]]></category>
		<category><![CDATA[notice-and-action procedures]]></category>
		<category><![CDATA[online marketplaces]]></category>
		<category><![CDATA[online medicine sales]]></category>
		<category><![CDATA[pharmaceutical advertising]]></category>
		<category><![CDATA[pharmaceutical distribution]]></category>
		<category><![CDATA[pharmaceutical law in Poland]]></category>
		<category><![CDATA[platform liability]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[prescription medicines]]></category>
		<category><![CDATA[product liability]]></category>
		<category><![CDATA[REACH]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[research chemicals]]></category>
		<category><![CDATA[research peptides in Poland]]></category>
		<category><![CDATA[research use only]]></category>
		<category><![CDATA[semaglutide regulation]]></category>
		<category><![CDATA[tirzepatide]]></category>
		<category><![CDATA[trade mark enforcement]]></category>
		<category><![CDATA[trader traceability]]></category>
		<category><![CDATA[unauthorised medicines]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=9029</guid>

					<description><![CDATA[<p>Publication date: November 16, 2026 Online sales of semaglutide and other active substances in Poland &#8211; regulatory exposure for sellers, marketplaces, advertisers and logistics operators Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/for-research-use-only-is-not-a-legal-shieldgg/">“For Research Use Only” Is Not a Legal Shieldgg</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: November 16, 2026</mark></strong></p>



<p><em>Online sales of semaglutide and other active substances in Poland &#8211; regulatory exposure for sellers, marketplaces, advertisers and logistics operators</em></p>



<p><strong>Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller&#8217;s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain &#8211; seller, marketplace, advertiser, influencer, payment or logistics provider &#8211; carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.</strong></p>



<span id="more-9029"></span>



<h1 class="wp-block-heading">Key takeaways for business</h1>



<ul class="wp-block-list">
<li>A “not for human consumption” or “research use only” disclaimer does not take a product outside the Pharmaceutical Law if the way it is presented, dosed and marketed points to use in humans.</li>



<li>Where a product meets the definition of a medicinal product and of another product category at the same time, the medicinal product regime prevails (Article 2(2) of Directive 2001/83/EC; Article 3a of the Pharmaceutical Law).</li>



<li>Sellers face criminal liability under the Pharmaceutical Law and the Criminal Code, as well as civil liability towards injured users.</li>



<li>Hosting providers and online marketplaces keep their liability exemption under the Digital Services Act (DSA) only as long as they act expeditiously once they know about an illegal offer. Since autumn 2026 Poland has a national DSA enforcement framework, and a further act on blocking orders and a register of domains has passed Parliament. Its closed catalogue of offences does not, however, cover offences under the Pharmaceutical Law.</li>



<li>The problem is less a gap in the law than fragmented and slow enforcement. Legitimate market participants &#8211; marketing authorisation holders, pharmacies, platforms and genuine laboratory suppliers &#8211; should treat this as a compliance and brand protection issue now.</li>
</ul>



<h1 class="wp-block-heading">A grey market growing next to a regulated one</h1>



<p>Online sales of active substances within the meaning of Article 2(38c) of the Polish Pharmaceutical Law<a href="#_ftn1" id="_ftnref1">[1]</a> have grown rapidly over the last few years. E-commerce allows sellers to reach a wide audience with substances of high biological activity: hormones, peptides, metabolic agents (such as semaglutide and tirzepatide), nootropics and anabolic compounds. The legality of this trade in Poland is governed by pharmaceutical, medical and criminal law.</p>



<p>The business model discussed here consists in placing on the market substances with a documented therapeutic or physiological effect while avoiding the requirements of the Pharmaceutical Law by means of a purely formal, linguistic device: the goods are described as “not for human consumption”, a “laboratory reagent”, a “substance for scientific purposes” or a “collector&#8217;s item”. Semaglutide, the active substance of authorised medicinal products such as Ozempic, Wegovy and Rybelsus, is a representative example. Alongside the legal pharmaceutical supply chain there is a grey online market in which semaglutide is sold as a lyophilised powder in vials labelled “for research purposes only”.</p>



<p>This raises a classification question with direct commercial consequences. The definition of a medicinal product (Article 2(32) of the Pharmaceutical Law) is based on the properties of the product &#8211; presented or actual &#8211; for preventing or treating disease. Marketing a substance with a proven biological effect under the guise of a chemical reagent is an attempt to circumvent administrative and criminal rules. In practice it creates an area of legal uncertainty in which freedom of economic activity and the free movement of goods meet the overriding priority of protecting public health.</p>



<h1 class="wp-block-heading">How the “research-only” model works</h1>



<p>The illegal trade in substances such as semaglutide in the Polish digital space has taken the form of an organised practice built on circumventing regulation. The number of offers to buy these sought-after substances without a prescription is rising sharply. Customers are directed to websites and social media profiles where they can order products with delivery straight to a parcel locker, which gives the buyer a sense of convenience and apparent discretion. The phenomenon is part of a wider European trend of illegal distribution of GLP-1 receptor agonists, against which the European Medicines Agency (EMA)<a href="#_ftn2" id="_ftnref2">[2]</a>, the World Health Organization (WHO) and the Polish authorities &#8211; the Chief Pharmaceutical Inspectorate (GIF) and the Office for Registration of Medicinal Products (URPL) &#8211; have issued public warnings.</p>



<p>The key to the model is the so-called “loophole”: products are labelled and positioned as “research substances”. Sellers offer them as “research peptides” or “research raw materials”, which is formally intended to remove responsibility for selling a medicinal product for human use. At the same time, the entire marketing setting &#8211; graphics, wording and tone of communication &#8211; clearly suggests a weight-loss effect and directly alludes to authorised prescription medicines. This allows sellers to sidestep the strict rules on the distribution of prescription-only medicines and makes it harder for the authorities to shut the activity down immediately.</p>



<p>The model carries direct and serious risks for the health and life of consumers. A person buying from an illegal source has no guarantee as to purity, actual composition, concentration or dose. The products are outside any quality oversight; vials may contain harmful excipients or contaminants, or doses different from those declared, which can lead to serious medical complications. In addition, transport outside a controlled cold chain may degrade the active substance, so that the final product is not only illegal but may also be ineffective or unsafe. For legitimate businesses, every such incident is also a reputational risk for the brand name that the illegal offer imitates.</p>



<h1 class="wp-block-heading">When does a product become a medicine? The two tests</h1>



<p>Classification as a medicinal product rests on two independent limbs derived from Article 1(2) of Directive 2001/83/EC<a href="#_ftn3" id="_ftnref3">[3]</a> and Article 2(32) of the Pharmaceutical Law<a href="#_ftn4" id="_ftnref4">[4]</a>: the presentation test and the function test. The first concerns how the product is perceived externally and, according to the Court of Justice of the European Union (CJEU), must be interpreted broadly. A product is a medicinal product by presentation if its packaging, leaflet, form or advertising gives an averagely well-informed consumer the impression that it has therapeutic or prophylactic properties (Case 227/82, Van Bennekom<a href="#_ftn5" id="_ftnref5">[5]</a>). The pharmaceutical form, such as capsules or tablets, is strong evidence of the seller&#8217;s intention to market the product as a medicinal product, but it is not conclusive in itself. The Court confirmed this in Case C-369/88, Delattre<a href="#_ftn6" id="_ftnref6">[6]</a>, which concerned products sold by mail order and labelled as not being medicinal products. It added that such a statement is evidence which the national court may take into account, but is not in itself conclusive &#8211; a point of direct relevance to “research use only” disclaimers. The Polish Supreme Administrative Court has reasoned along the same lines in a food supplement labelling case: a product to which disease prevention or treatment properties are attributed is not a food supplement but a medicinal product<a href="#_ftn7" id="_ftnref7">[7]</a>. On that basis the court upheld a fine imposed by the sanitary authorities, and confirmed by the Chief Sanitary Inspector, for labelling that suggested such properties.</p>



<p>The function test refers to the actual biological effect of the product on the human body, regardless of promotional claims or the manufacturer&#8217;s declarations. Here the classifying authority, including the URPL, cannot base its decision solely on the presence or quantity of a given active substance. The assessment must be made case by case, taking account of all the characteristics of the product. According to the CJEU, a product is not a medicinal product by function where, having regard to its composition, including its content of active substances, and if used as intended, it is incapable of appreciably restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action<a href="#_ftn8" id="_ftnref8">[8]</a>. This requires a detailed analysis of biological properties and of the real impact of the substance on physiological processes. The CJEU has clarified the notion of “pharmacological action” in Case C-308/11, Chemische Fabrik Kreussler<a href="#_ftn9" id="_ftnref9">[9]</a>: the substance does not have to interact with a cellular constituent of the user&#8217;s own body, and interaction with any cellular constituent present in the body, such as bacteria, may be sufficient. It has also held that substances which merely modify physiological functions without being capable of any beneficial effect on human health, and which are consumed solely to induce intoxication, are not medicinal products (Joined Cases C-358/13 and C-181/14, D. and G.<a href="#_ftn10" id="_ftnref10">[10]</a>). That limitation does not assist sellers of semaglutide: it is the active substance of authorised medicines with an established therapeutic effect.</p>



<p>The relationship between the medicinal product regime and other regulatory regimes is governed by the conflict rule in Article 2(2) of Directive 2001/83/EC, mirrored in Article 3a of the Pharmaceutical Law. Where a product, taking into account all its characteristics, may fall both within the definition of a medicinal product and within that of another product category &#8211; for example a cosmetic, a medical device or a food supplement &#8211; the medicinal product rules prevail. The CJEU has made clear that this rule applies to products whose status as a medicinal product has been scientifically established, not to products for which it merely cannot be excluded (Case C-140/07, Hecht-Pharma<a href="#_ftn11" id="_ftnref11">[11]</a>). The purpose is to ensure a high level of public health protection by subjecting such products to the authorisation and control procedures of the pharmaceutical market.</p>



<h1 class="wp-block-heading">The “research material” label under Polish law</h1>



<p>Offering a substance with the annotation “research material” or “for laboratory use” does not automatically release the seller from the requirements of Polish law. Under Article 2(38) of the Pharmaceutical Law, a substance is any matter of human, animal, plant or chemical origin. The classification of the goods depends on their actual intended use, presentation and biological profile. Labelling a product “for research purposes” therefore does not prevent the authorities from treating it as a medicinal product, a food supplement or a novel food if the circumstances show that it is intended for consumption or use in humans.</p>



<p>If the substance offered has properties for preventing or treating disease, or is presented in a way that suggests such an effect (for example through dosing information, instructions for use or social media advertising), it is subject to the Pharmaceutical Law. Placing a medicinal product on the market without a marketing authorisation is a criminal offence (Article 124 of the Pharmaceutical Law). A declaration that the product is “intended solely for research” is likely to be treated as an attempt to circumvent the law where the seller&#8217;s overall conduct shows commercial distribution to consumers.</p>



<p>Trade in genuine research substances and chemicals is subject to separate EU and national chemical safety rules, in particular the REACH<a href="#_ftn12" id="_ftnref12">[12]</a> and CLP<a href="#_ftn13" id="_ftnref13">[13]</a> Regulations. A seller of chemicals intended for laboratory research must classify and label them correctly and provide a safety data sheet. Where the substance is psychoactive, the Act on Counteracting Drug Addiction<a href="#_ftn14" id="_ftnref14">[14]</a> applies irrespective of the trade name or declared research status, with criminal sanctions and administrative measures enforced by the State Sanitary Inspection. For legitimate laboratory suppliers the point is practical: selling to verified professional customers, with proper documentation, is what distinguishes a research chemical business from a disguised consumer channel.</p>



<h1 class="wp-block-heading">Distribution, marketing and cross-border supply: where the exposure sits</h1>



<p>Distribution of semaglutide preparations outside the official pharmacy channel takes place largely online. Distributors categorise products as “research peptides” or “substances for laboratory use”, or add a “research only” clause. The supply chain is optimised for discretion and convenience: orders are placed through web shops and social media profiles, and physical delivery is made through parcel lockers or couriers, which makes it difficult for supervisory authorities to inspect consignments at the delivery stage and removes any check of the buyer&#8217;s age or identity. Storage of consignments in parcel lockers at extreme temperatures (summer heat or winter frost) may additionally degrade peptides, so that the user may inject a degraded product.</p>



<p>On the marketing side, sellers use several persuasion strategies which, despite formal “research use” disclaimers, clearly suggest a weight-loss and therapeutic effect. Advertising is optimised for search phrases such as “Ozempic alternative” or “semaglutide without prescription” and supported by promotional content on social media and internet forums. Price comparison tools and informal recommendation marketing (for example endorsement by a well-known influencer) create an impression that the purchase is common, accessible and relatively safe, although the product in fact requires medical supervision and a prescription. Advertising medicinal products that are not authorised in Poland is itself an offence (Article 129 of the Pharmaceutical Law), which is directly relevant for agencies, publishers and influencers.</p>



<p>The most complex dimension is cross-border import and falsification, in line with the global trend identified by the WHO and the EMA. The raw material or ready vials and pens reach the EU market mainly from third countries (including Asia), often bypassing EU customs procedures and pharmaceutical inspection. The products do not undergo mandatory testing of purity, concentration of the active substance or stability under cold chain conditions. Import outside the legal supply chain therefore carries a critical risk of contaminated, wrongly dosed or inactive products entering the market.</p>



<h1 class="wp-block-heading">Who is liable? Sellers, platforms and advertisers</h1>



<p>The starting point is the Pharmaceutical Law. Under Article 124, placing a medicinal product on the market, or storing it for that purpose, without a marketing authorisation is punishable by a fine, restriction of liberty or imprisonment for up to two years. Carrying on business in the trade of medicinal products without the required permit is a separate and more serious offence, punishable by a fine, restriction of liberty or imprisonment from three months to five years (Article 125(2)(2)). Retail trade in medicinal products is reserved to pharmacies (Article 68(1)), and mail-order sale is permitted only for non-prescription medicines and only by licensed pharmacies and pharmacy outlets (Article 68(3)). Prescription-only medicines such as semaglutide therefore cannot lawfully be sold by mail order at all. Supplying or storing falsified medicinal products or falsified active substances is subject to more severe penalties, up to five years&#8217; imprisonment (Article 124b), which is directly relevant to illegal web shops offering imitation pens or substances that are falsely presented as to their identity or source.</p>



<p>The position of online intermediaries is governed by the Digital Services Act<a href="#_ftn15" id="_ftnref15">[15]</a> together with national consumer protection law. The DSA maintains the principle that there is no general obligation to monitor content (Article 8). However, a hosting provider loses the liability exemption under Article 6 if, upon obtaining actual knowledge or awareness of the illegal nature of an offer (for example through a notice under Article 16), it fails to act expeditiously to remove or disable access to it. Online marketplaces must in addition verify the traceability of traders (Article 30). In Poland, the Act of 4 September 2026<a href="#_ftn16" id="_ftnref16">[16]</a>, in force since 6 November 2026, designated the President of the Office of Electronic Communications (UKE) as Digital Services Coordinator. The President of the Office of Competition and Consumer Protection (UOKiK) is the competent authority for the obligations of online platforms that allow consumers to conclude distance contracts with traders (Chapter III, Section 4 of the DSA, which includes trader traceability) and for other DSA infringements that harm consumer interests. In this respect online marketplaces are therefore supervised by UOKiK. Independently, UOKiK may impose significant fines for practices infringing collective consumer interests, and the Chief Pharmaceutical Inspector may order withdrawals and impose administrative fines under the Pharmaceutical Law.</p>



<p>Sellers also face liability under the Criminal Code for endangering life or health &#8211; in particular Article 165 § 1(2) (causing danger to the life or health of many persons by placing on the market substances harmful to health or pharmaceutical products that do not meet quality requirements) and Article 160 (exposing a person to direct danger of loss of life or serious injury). Describing products as “research peptides” does not release a business from criminal liability on the basis of a mistake of law or an appearance of legality where the products are in fact intended and advertised for human use. Finally, entities offering illegal preparations are fully liable in tort to consumers for damage to health caused by a product that is substandard, toxic or of unknown origin.</p>



<h1 class="wp-block-heading">Enforcement outlook: fragmented rules, new blocking tools</h1>



<p>The regulatory gap in the online trade in active substances does not result from a lack of rules but from their fragmentation and from enforcement difficulties. The core problem is a grey zone that exploits the “research purposes” classification. The State Pharmaceutical Inspection and law enforcement authorities face evidentiary barriers and lengthy procedures when dealing with operators who quickly change domains, jurisdictions and corporate names. A regime based on reacting after a product has been placed on the market is not effective enough against mass, automated e-commerce.</p>



<p>The legislative landscape is changing. In addition to the September 2026 act establishing national DSA oversight, Parliament has adopted a further amendment to the Act on the Provision of Electronic Services, the Act of 22 October 2026<a href="#_ftn17" id="_ftnref17">[17]</a>. It introduces orders to disable access to illegal content, issued by the President of UKE (or by the Chairman of the National Broadcasting Council for video-sharing platforms), and a register of internet domains used to disseminate such content, kept by the President of UKE. Internet access providers will have to block a registered domain within 48 hours. The act was sent to the President of Poland, whose decision was pending at the time of writing, and is to enter into force three months after publication.</p>



<p>For the trade discussed here the new mechanism has an important limit. Orders may be issued only for content linked to a closed catalogue of offences, and that catalogue does not include the offences under the Pharmaceutical Law or Article 165 of the Criminal Code. An illegal offer of “research” semaglutide can therefore be caught only indirectly, for example where it involves fraud (Article 286 of the Criminal Code) or goods bearing a counterfeit trade mark (Article 305 of the Industrial Property Law). Applications may be filed by a prosecutor, the Police, the National Revenue Administration, copyright holders and service recipients; the Chief Pharmaceutical Inspector is not named among the applicants. In our view, sector-specific measures therefore remain necessary: clear powers for the Chief Pharmaceutical Inspector to initiate rapid blocking of sites and domains offering illegal medicines, and rules on trade in peptides and other biologically active substances making clear that a “research use” declaration does not displace classification as a medicinal product where the presentation points to a therapeutic purpose.</p>



<p>A systemic response also requires close inter-agency cooperation and integrated controls at the EU&#8217;s borders. We recommend dedicated task forces bringing together the GIF, the National Revenue Administration (KAS), the Police and UOKiK to monitor cross-border courier and postal consignments delivered to parcel lockers. Legal changes should be complemented by public education, conducted together with the medical and pharmacists&#8217; self-governing bodies, on the health risks of products of unknown origin and on using only authorised online pharmacies bearing the common EU logo.</p>



<h1 class="wp-block-heading">What businesses should do now</h1>



<ul class="wp-block-list">
<li><strong>Marketplaces and hosting providers: </strong>review notice-and-action procedures and trader verification for listings of peptides, “research chemicals” and GLP-1 related keywords, and document response times.</li>



<li><strong>Marketing authorisation holders and brand owners: </strong>monitor online offers that allude to authorised brands, use DSA notices and trade mark rights (offers of goods bearing a counterfeit trade mark fall within the new blocking procedure), and report suspected falsified products to the GIF.</li>



<li><strong>Advertisers, agencies and influencers: </strong>do not promote products that allude to prescription medicines; a “research only” disclaimer in the offer does not protect the advertiser.</li>



<li><strong>Laboratory and chemical suppliers: </strong>sell to verified professional customers only, keep REACH and CLP documentation in order and avoid any presentation that suggests use in humans.</li>



<li><strong>Logistics and payment providers: </strong>include this product category in risk assessments and in cooperation procedures with the authorities.</li>
</ul>



<p><em>State of the law as at 10 November 2026. This article is for general information and does not constitute legal advice.</em></p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a> Act of 6 September 2001 &#8211; Pharmaceutical Law (consolidated text: Journal of Laws [Dz. U.] of 2026, item 612, as amended); hereinafter the “Pharmaceutical Law”.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a> European Medicines Agency and Heads of Medicines Agencies, “Warning about sharp rise in illegal medicines sold in the EU”, September 2025.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a> Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67). The Directive is due to be replaced by a new directive under the EU pharmaceutical package; the Council adopted its first-reading position on 28 September 2026 and the final adoption steps were under way at the time of writing.</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a> Under Article 2(32) of the Pharmaceutical Law, a medicinal product is a substance or combination of substances presented as having properties for preventing or treating disease in humans or animals, or administered with a view to making a diagnosis or to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a> Judgment of the Court of Justice of 30 November 1983, Case 227/82, Van Bennekom, ECLI:EU:C:1983:354, paras 17-19 (decided under Directive 65/65/EEC, the predecessor of Directive 2001/83/EC).</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a> Judgment of the Court of Justice of 21 March 1991, Case C-369/88, Delattre, ECLI:EU:C:1991:137, paras 38-41 (also decided under Directive 65/65/EEC).</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a> Judgment of the Supreme Administrative Court (NSA) of 1 September 2015, II OSK 14/14, LEX no. 1987032.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a> Judgment of the Court of Justice of 15 January 2009, Case C-140/07, Hecht-Pharma, ECLI:EU:C:2009:5, paras 39-42 and point 3 of the operative part.</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a> Judgment of the Court of Justice of 6 September 2012, Case C-308/11, Chemische Fabrik Kreussler, ECLI:EU:C:2012:548, paras 31-36.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a> Judgment of the Court of Justice of 10 July 2014, Joined Cases C-358/13 and C-181/14, D. and G., ECLI:EU:C:2014:2060.</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a> Case C-140/07, Hecht-Pharma, cited above, paras 24-29 and point 1 of the operative part.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a> Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a> Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures (CLP).</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a> Act of 29 July 2005 on Counteracting Drug Addiction (consolidated text: Journal of Laws of 2023, item 1939, as amended).</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a> Regulation (EU) 2022/2065 of the European Parliament and of the Council of 19 October 2022 on a Single Market For Digital Services (Digital Services Act).</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a> Act of 4 September 2026 amending the Act on the Provision of Electronic Services and certain other acts (Journal of Laws of 2026, item 1296), published on 6 October 2026; see the new Articles 15a and 15b of the Act on the Provision of Electronic Services.</p>



<p><a id="_ftn17" href="#_ftnref17">[17]</a> Act of 22 October 2026 amending the Act on the Provision of Electronic Services and certain other acts (Sejm print no. 2693, text finally adopted after consideration of the Senate&#8217;s amendments), adding Articles 11a-11s to the Act on the Provision of Electronic Services; not yet published at the time of writing.</p>
<p> </p>



<h2 class="wp-block-heading">Services</h2>



<p><strong>KIELTYKA GLADKOWSKI</strong> is a Polish business law firm headquartered in Warsaw and Krakow, with a New York office under the iSTART1 brand. Building on a practice dating back to 1981, we advise clients in the following areas.</p>



<h1 class="wp-block-heading">Explore our services</h1>



<p>Select a practice area to learn more.</p>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td><strong>Business<br>&amp; Finance</strong></td><td><strong>Technology<br>&amp; IP</strong></td><td><strong>Energy<br>&amp; Projects</strong></td><td><strong>Sectors &amp;<br>Cross Border</strong></td><td><strong>Private Clients<br>&amp; Disputes</strong></td></tr></thead><tbody><tr><td><a href="https://www.kg-legal.pl/investment-law-and-processes-in-poland-1/">Commercial &amp; Corporate</a> <a href="https://www.kg-legal.eu/polish-limited-liability-company-legal-support-in-operational-business-maintenance-and-representation-of-shareholders-in-court/">Polish LLCs</a> <a href="https://www.kg-legal.eu/employment-law-and-collective-labour-law-in-poland-including-employment-contracts/">Employment Law</a></td><td><a href="https://www.kg-legal.pl/it-bio-it-new-technologies-media-law-1/">IT, IP, Media &amp; New Tech</a> <a href="https://www.kg-legal.eu/trademarks-and-brand-protection/">Trademarks &amp; Brand Protection</a></td><td><a href="https://www.kg-legal.eu/green-transition/">Green Transition</a> <a href="https://www.kg-legal.eu/energy-transformation-in-poland-main-assumptions-of-the-polish-energy-policy-2040-2/">Energy Policy 2040</a></td><td><a href="https://www.kg-legal.pl/pharmaceutical-life-sciences-healthcare-law-1/">Pharma, Life Sciences &amp; Healthcare</a> <a href="https://www.kg-legal.eu/pharmaceutical-law/">Pharmaceutical Law</a></td><td><a href="https://www.kg-legal.eu/private-client-desk/">Private Client Desk</a> <a href="https://www.kg-legal.eu/hnw-and-next-gen-wealth/">HNW &amp; Next Gen Wealth</a></td></tr><tr><td><a href="https://www.kg-legal.eu/venture-capital-and-private-equity/">Venture Capital &amp; Private Equity</a> <a href="https://www.kg-legal.eu/stock-exchange-and-securities-law-in-poland/">Stock Exchange &amp; Securities</a> <a href="https://www.kg-legal.eu/markets-in-modern-and-conventional-financial-instruments-including-tokens-crypto-assets-packaged-retail-and-insurance-based-investment-products/">Financial Instruments &amp; Crypto</a></td><td><a href="https://www.kg-legal.eu/artificial-intelligence-ai-law-poland-eu/">AI Sector</a> <a href="https://www.kg-legal.eu/data-centers/">Data Centers</a></td><td><a href="https://www.kg-legal.eu/regulatory-law-of-the-energy-sector-in-poland/">Energy Sector</a> <a href="https://www.kg-legal.eu/green-energy-law-renewable-energy-law/">Renewable Energy</a></td><td><a href="https://www.kg-legal.eu/medical-devices-including-medical-devices-law-under-combined-atmps/">Medical Devices</a> <a href="https://www.kg-legal.eu/food-law/">Food Law</a></td><td><a href="https://www.kg-legal.eu/international-divorces/">International Divorces</a> <a href="https://www.kg-legal.eu/international-family-law/">International Family Law</a></td></tr><tr><td><a href="https://www.kg-legal.eu/agreements-and-contracts/">Agreements &amp; Contracts</a> <a href="https://www.kg-legal.eu/contracts-in-the-international-trade-smart-contracts/">International Trade &amp; Smart Contracts</a></td><td><a href="https://www.kg-legal.eu/data-privacy-and-data-protection/">Data Privacy &amp; Protection</a> <a href="https://www.kg-legal.pl/cybersecurity/">Cybersecurity</a></td><td><a href="https://www.kg-legal.eu/biofuels-and-biocomponents/">Biofuels &amp; Biocomponents</a> <a href="https://www.kg-legal.eu/offshore-wind-farms/">Offshore Wind</a></td><td><a href="https://www.kg-legal.eu/art-market/">Art Market</a> <a href="https://www.kg-legal.eu/legal-services-in-fashion-law/">Fashion</a></td><td><a href="https://www.kg-legal.eu/cross-border-inheritance-matters/">Cross Border Inheritance</a> <a href="https://www.kg-legal.eu/immigration-law-business-immigration-polish-passport/">Immigration &amp; Polish Passports</a></td></tr><tr><td><a href="https://www.kg-legal.eu/offshore-companies-tax-optimization/">Offshore Companies &amp; Tax</a></td><td><a href="https://www.kg-legal.eu/distributed-ledger-technology-law/">Distributed Ledger Technology</a> <a href="https://www.kg-legal.eu/metaverse-and-web3-legal-environment/">Metaverse &amp; Web3</a></td><td><a href="https://www.kg-legal.eu/greenfield-in-poland/">Greenfield Investment</a> <a href="https://www.kg-legal.eu/kieltyka-gladkowski-provides-assistance-in-the-area-of-european-partnerships-in-horizon-europe-programme/">Horizon Europe</a></td><td><a href="https://www.kg-legal.pl/cross-border-cases-1/">Cross Border Practice</a> <a href="https://www.kg-legal.eu/customs-and-tariffs-support-for-international-traders-in-poland-and-eu/">Customs &amp; Tariffs</a></td><td><a href="https://www.kg-legal.eu/asset-tracing-in-poland-for-international-creditors/">Asset Tracing in Poland</a> <a href="https://www.kg-legal.eu/asset-tracing/">Asset Tracing</a> <a href="https://www.kg-legal.eu/business-investigations-private-detective-services/">Business Investigations</a></td></tr><tr><td><a href="https://www.kg-legal.eu/dissolution-and-liquidation-of-capital-companies/">Company Dissolution &amp; Liquidation</a> <a href="https://www.kg-legal.eu/cross-border-bankruptcy-in-poland/">Cross Border Bankruptcy</a></td><td><a href="https://www.kg-legal.eu/dual-use-technology-law/">Dual Use Technology</a> <a href="https://www.kg-legal.eu/drone-uas-law/">Drones &amp; UAS</a> <a href="https://www.kg-legal.eu/defence-and-space-sector/">Defence &amp; Space</a></td><td><a href="https://www.kg-legal.eu/industrial-micro-and-public-macro-infrastructure/">Infrastructure</a> <a href="https://www.kg-legal.eu/construction/">Construction</a> <a href="https://www.kg-legal.eu/public-private-partnerships/">Public Private Partnerships</a></td><td><a href="https://www.kg-legal.eu/sworn-certified-legal-translations-of-documents-and-contracts/">Sworn &amp; Certified Legal Translations</a></td><td><a href="https://www.kg-legal.eu/litigation-and-representation-of-international-clients-before-the-polish-courts/">Litigation in Polish Courts</a> <a href="https://www.kg-legal.eu/litigation-antitrust-and-competition-law/">Litigation &amp; Competition</a></td></tr></tbody></table></figure>



<p>Service directory: <a href="https://www.kg-legal.eu/services/">kg-legal.eu/services</a></p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/for-research-use-only-is-not-a-legal-shieldgg/">“For Research Use Only” Is Not a Legal Shieldgg</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/for-research-use-only-is-not-a-legal-shieldgg/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Ageing biomarkers as evidence of geroprotective efficacy</title>
		<link>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/ageing-biomarkers-as-evidence-of-geroprotective-efficacy/</link>
					<comments>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/ageing-biomarkers-as-evidence-of-geroprotective-efficacy/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 16:55:21 +0000</pubDate>
				<category><![CDATA[IT, NEW TECHNOLOGIES, MEDIA AND COMMUNICATION TECHNOLOGY LAW]]></category>
		<category><![CDATA[Ageing Biomarkers]]></category>
		<category><![CDATA[Biobanking]]></category>
		<category><![CDATA[Biological Age]]></category>
		<category><![CDATA[Biological Samples]]></category>
		<category><![CDATA[Biomarker Validation]]></category>
		<category><![CDATA[Clinical Evidence]]></category>
		<category><![CDATA[Clinical Trial Design]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Clinical Trials Regulation]]></category>
		<category><![CDATA[Companion Diagnostics]]></category>
		<category><![CDATA[CTIS]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Epigenetic Clocks]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[Genetic Data]]></category>
		<category><![CDATA[Geroprotection]]></category>
		<category><![CDATA[Geroprotectors]]></category>
		<category><![CDATA[Health Claims]]></category>
		<category><![CDATA[Healthy Ageing]]></category>
		<category><![CDATA[In Vitro Diagnostics]]></category>
		<category><![CDATA[informed consent]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[IVDR]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Longevity Research]]></category>
		<category><![CDATA[Medical Device Software]]></category>
		<category><![CDATA[Non-Commercial Clinical Trials]]></category>
		<category><![CDATA[Patent Protection]]></category>
		<category><![CDATA[Performance Studies]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Research Commercialisation]]></category>
		<category><![CDATA[Research Ethics]]></category>
		<category><![CDATA[Surrogate Endpoints]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8985</guid>

					<description><![CDATA[<p>Publication date: November 10, 2026 Clinical research, diagnostic testing and commercialisation under Polish and EU law Law as at 5 November 2026 Abstract A change in an epigenetic clock may justify further investigation of a medicine. Its value as evidence of benefit depends on what the clock measures, the population in which it has been [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/ageing-biomarkers-as-evidence-of-geroprotective-efficacy/">Ageing biomarkers as evidence of geroprotective efficacy</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color"><strong>Publication date: November 10, 2026</strong></mark></p>



<p>Clinical research, diagnostic testing and commercialisation under Polish and EU law</p>



<p><em>Law as at 5 November 2026</em></p>



<p>Abstract</p>



<p>A change in an epigenetic clock may justify further investigation of a medicine. Its value as evidence of benefit depends on what the clock measures, the population in which it has been validated and whether treatment effects on the score predict effects on health. The same assay may be used to analyse archived samples, select participants for treatment or sell a test to consumers. Each use raises a different legal question. This article traces those questions from trial design through to commercial use, with particular attention to Polish law on medical experiments, performance studies, access to medical records and the use of data from non-commercial clinical trials.</p>



<p><strong>Keywords&nbsp; </strong>ageing biomarkers, geroprotectors, clinical trials, IVDR, biobanks, genetic data</p>



<span id="more-8985"></span>



<h2 class="wp-block-heading">What three years on a biological clock mean</h2>



<p>Suppose researchers measure DNA methylation in volunteers’ blood before administering a substance and again six months later. In the intervention group, the mean score on the chosen clock falls by three years. The sponsor wants to describe the result as evidence that the product slows ageing. The first question concerns the comparator. Was the difference from placebo also three years, or does the figure describe only the change between two measurements in the same people? The second concerns the volunteers. Does a change of this size predict a later loss of independence, fewer hospital admissions or longer survival? Each claim calls for different evidence.<a href="#_ftn1" id="_ftnref1">[1]</a></p>



<p>A geroprotector, as used here, is a substance under investigation for its potential effect on biological processes associated with ageing. A model can be trained to estimate chronological age, mortality risk or the pace of physiological change. Two models that express their results in years can therefore be measuring different things. In an open-label pilot study in people with diabetic kidney disease, investigators reported fewer cells expressing markers of cellular senescence, including p16 and p21, in adipose tissue after dasatinib and quercetin. This provided evidence about a possible mechanism of these senolytic drugs. Establishing whether the intervention prolongs healthy life requires a study measuring that benefit or a reliable surrogate for it.<a href="#_ftn2" id="_ftnref2">[2]</a></p>



<p>The European Innovation Council recognised this problem in its Pathfinder challenge on Biotechnology for Healthy Ageing. For biomarker tools, the programme linked access to appropriate cohorts with the need to demonstrate a relationship between an ageing mechanism and clinical features. These conditions identify a research objective. Whether the results support a particular medicinal indication is a separate regulatory assessment.<a href="#_ftn3" id="_ftnref3">[3]</a></p>



<h1 class="wp-block-heading">From a biomarker association to a clinical benefit</h1>



<p>An ageing biomarker may identify a group at increased risk of functional decline. Such a prognostic marker makes events more likely to be observed during the study. A predictive marker helps identify patients likely to derive a greater effect from a particular treatment. A pharmacodynamic response marker serves another purpose. A change may show that the substance affects the biological pathway under investigation. If the sponsor uses that change to predict something that matters to patients, the marker is being proposed as a surrogate endpoint. The strength of that case depends on the biological rationale, the marker’s prognostic value and interventional evidence that treatment effects on the marker correspond to treatment effects on the clinical outcome.<a href="#_ftn4" id="_ftnref4">[4]</a></p>



<p>The CALERIE trial illustrates the distinction. In a post hoc analysis of samples from this randomised study of caloric restriction, the intervention slowed the pace of ageing measured by DunedinPACE. The authors found no significant change in the biological age estimates produced by PhenoAge and GrimAge. In a separate study, TranslAGE researchers applied 16 clocks to data from 51 interventional studies. Responsiveness varied with the intervention, population and length of follow-up. For a lawyer reviewing a regulatory dossier, the choice of clock is therefore material. Selecting the most favourable measure after inspecting the results weakens the inference, particularly when the investigators have made numerous comparisons. Whether the population studied resembles the population for the intended efficacy claim is a further question.<a href="#_ftn5" id="_ftnref5">[5]</a></p>



<p>A protocol should specify the algorithm version, tissue, sampling time, primary comparison and approach to multiplicity and missing measurements. A study of loss of independence also has to address what happens if a participant dies before the next functional assessment. An analysis confined to those who are well enough to attend the visit could give an overly favourable picture. ICH E9(R1) provides a way to link these decisions to the precise treatment effect the trial is intended to estimate. Choices made on this point can change the clinical meaning of the answer even if the assay is perfectly reproducible.<a href="#_ftn6" id="_ftnref6">[6]</a></p>



<p>Where a method is intended for use by several medicine developers, the European Medicines Agency (EMA) offers voluntary qualification within a defined context of use. Its Committee for Medicinal Products for Human Use (CHMP) may, for example, assess whether the tool is suitable for identifying a higher-risk population. Using the same tool as a primary endpoint requires a case for that additional purpose. Where the question concerns the design of one product development programme, the sponsor can seek scientific advice on the protocol.<a href="#_ftn7" id="_ftnref7">[7]</a></p>



<h1 class="wp-block-heading">Classifying the substance and choosing the study design</h1>



<p>The biological nature of ageing does not by itself determine product classification or establish a proposed indication. Under EU and Polish law, a substance may be a medicinal product because it is presented as treating or preventing disease. It may also qualify because it can be used to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action. In Hecht-Pharma, the Court of Justice held that the product must be assessed individually, taking account of factors including composition, dose and effects under normal conditions of use. Giving medicines legislation priority in a borderline case still requires a finding that the product meets the definition of a medicine.<a href="#_ftn8" id="_ftnref8">[8]</a></p>



<p>This distinction affects population selection. A study of whether treatment delays mobility loss in people at increased risk can define an event and a period of observation. A project in healthy adults that measures only a cellular marker will answer a narrower question. Experience with metformin in a different indication contributes knowledge about the substance. A new use still requires its own assessment of dose, duration, population and benefit–risk balance. A clinical trial authorisation allows the evidence to be generated. Bringing a new medicine to market or adding an indication to an existing authorisation requires a separate procedure. The authority considers, among other matters, whether therapeutic efficacy is substantiated and the benefit–risk balance is favourable for the proposed use.<a href="#_ftn9" id="_ftnref9">[9]</a></p>



<p>The interventions in the protocol then determine the legal route. Under Regulation (EU) No 536/2014 (the Clinical Trials Regulation, or CTR), a clinical study of a medicinal product constitutes a clinical trial if any one of the statutory criteria is satisfied. They include advance assignment to a therapeutic strategy outside normal practice, a prescribing decision taken together with the decision to enrol the participant or diagnostic or monitoring procedures additional to normal care. Observing treatment prescribed independently of enrolment can constitute a non-interventional study if the other criteria are also absent. Extra blood draws required by the protocol therefore merit scrutiny even if the medicine is already available from a pharmacy.<a href="#_ftn10" id="_ftnref10">[10]</a></p>



<p>A low-intervention trial is still a clinical trial. Apart from placebos, the investigational medicines must be authorised. Their use must conform to the authorisation or be supported by published scientific evidence of safety and efficacy in at least one Member State concerned. Additional procedures must pose no more than minimal additional risk or burden compared with normal clinical practice. An earlier stage of a programme may involve animal experiments. In Poland, these require authorisation by the competent local ethics committee. The assessment considers replacement of animals by other methods, reduction of animal numbers and refinement of procedures.<a href="#_ftn11" id="_ftnref11">[11]</a></p>



<h1 class="wp-block-heading">Protecting participants in a Polish clinical trial</h1>



<p>Applications for medicinal product trials are submitted through the EU Clinical Trials Information System (CTIS). In a multinational trial, Part I of the assessment covers matters including the scientific rationale and benefit–risk balance. In Part II, each Member State concerned considers national matters including participant information, consent, recruitment and arrangements for compensation. The Polish decision is issued by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). The ethical assessment is carried out by the national bioethics committee or a designated committee on the statutory list.<a href="#_ftn12" id="_ftnref12">[12]</a></p>



<p>A healthy volunteer may have little prospect of a direct benefit from a preventive intervention. The application should explain what potential value to participants or public health justifies the foreseeable risks and inconvenience. In older populations, multimorbidity, concurrent medicines and the burden of study visits affect that assessment. EMA recommends the Short Physical Performance Battery to characterise physical frailty at baseline. It helps establish whom the study population represents. A proposal to use the same scale as the main measure of efficacy needs a justification appropriate to the indication.<a href="#_ftn13" id="_ftnref13">[13]</a></p>



<p>The English MET-PREVENT trial shows why that distinction matters. In older people with probable sarcopenia and physical prefrailty or frailty, metformin did not improve four-metre walking speed at four months compared with placebo. The authors also reported poor tolerability in this population. That finding concerns a particular dose, population and functional outcome. In another trial, a promising change in a laboratory marker would still have to be interpreted alongside tolerability, adverse events and the participant’s ability to function in daily life.<a href="#_ftn14" id="_ftnref14">[14]</a></p>



<p>Chronological age does not determine the ability to give informed consent. For participants who lack that capacity, Article 31 CTR requires, among other safeguards, consent from a legally designated representative, respect for the express wish of a participant capable of forming an opinion and a justification for studying that population. The sponsor must also plan safety oversight, reporting of suspected unexpected serious adverse reactions and publication of results with a lay summary, generally within one year of the end of the trial in all Member States concerned. Polish law addresses civil liability and insurance, with an exception to the sponsor’s insurance obligation for low-intervention trials. The Clinical Trials Compensation Fund provides a separate route to compensation, including for bodily injury or a health impairment resulting from trial participation.<a href="#_ftn15" id="_ftnref15">[15]</a></p>



<h1 class="wp-block-heading">When a biomarker assay falls within the IVDR</h1>



<p>Regulation (EU) 2017/746 (the IVDR) governs devices intended to examine specimens from the human body, including software with the relevant intended purpose. The biological properties of the marker and the intended use of the tool that measures it are distinct issues. A retrospective analysis of blinded samples may examine whether changes in methylation correlate with subsequent functional decline. Where the result plays no part in participant management, the assay may have an exclusively research purpose. If the same result determines enrolment, assignment to a medicine or discontinuation of treatment, a decision about an individual now depends on it. Assessment must take account of the manufacturer’s intended purpose, instructions, promotional statements and actual role in the protocol. A “research use only” label cannot resolve the issue on its own.<a href="#_ftn16" id="_ftnref16">[16]</a></p>



<p>Consider the clock again. Dividing participants into subgroups for later statistical analysis has different implications from withholding the medicine from an individual whose score falls below a threshold. Companion diagnostic (CDx) status has a narrower test. The device must be essential for the safe and effective use of a corresponding medicine and identify people likely to benefit or those at increased risk of serious adverse reactions. As a rule, a companion diagnostic is a class C device under IVDR rule 3(f). In the conformity assessment, the notified body consults a competent medicines authority or EMA, as appropriate for the medicinal product.<a href="#_ftn17" id="_ftnref17">[17]</a></p>



<p>The performance evaluation addresses the scientific validity of the association between the measured feature and a clinical condition, analytical performance and clinical performance. An assay can measure methylation accurately yet assign patients to the wrong treatment group, for example if the threshold was derived in a younger population. Documentation should address the consequences of false positive and false negative results. The intended use covered by an existing CE mark must be checked against the proposed new purpose. Evidence that the assay performs as intended does not establish that the medicine works.<a href="#_ftn18" id="_ftnref18">[18]</a></p>



<p>Under the standard Polish procedure, a medicinal product trial and a device performance study requiring authorisation are assessed separately. URPL specifies an ethics opinion and authorisation by its President for a CDx performance study using samples collected specifically for that purpose. CDx studies using only left-over samples are subject to notification. The EU COMBINE pilot coordinates reviews of selected multinational combined studies. Poland is not listed among the participating countries in Annex I to the phase two sponsor guide. A sponsor therefore needs to plan the Polish national route even where sites elsewhere in the same project participate in the pilot.<a href="#_ftn19" id="_ftnref19">[19]</a></p>



<h1 class="wp-block-heading">Software and the result delivered to a patient</h1>



<p>An ageing clock may be a statistical model, stand-alone medical software or a component of a diagnostic system. A program designed to interpret specimen results and provide medical information about an individual may fall under the IVDR. Software that draws on gait sensors and supports a diagnostic or therapeutic decision may instead fall under Regulation (EU) 2017/745 (the MDR). For a model that combines laboratory results, images and clinical history, the function of each module and the principal source of the information used for the decision matter. The manufacturer’s description should be tested against what users actually receive and what the product invites them to do.<a href="#_ftn20" id="_ftnref20">[20]</a></p>



<p>An application might provide general educational information on ageing. A different question arises if its report states that the customer’s profile warrants a particular therapy. Before deployment, the developer needs to establish the limits of validation, how uncertainty is communicated and how the algorithm performs across age groups and in people with multiple conditions. An update to the model or threshold may change how many patients are offered treatment. Preserving the trial version, recording changes and evaluating their effects makes it possible to reconstruct the basis for an individual decision.</p>



<p>If the software also meets the definition of an AI system, Article 6(1) of the AI Act requires a separate assessment. It covers an AI system that is a product, or a safety component of a product, subject to Union legislation listed in Annex I where third-party conformity assessment is required for that product. Regulation (EU) 2026/1744 moved the application of the high-risk requirements for this group to 2 August 2028. An exclusion for systems developed and put into service solely for scientific research and development requires reassessment when the system becomes part of a clinical offering. Medical device requirements apply on their own timetable.<a href="#_ftn21" id="_ftnref21">[21]</a></p>



<p>Polish laboratory medicine law regulates the activities of medical laboratories and the reporting of results to patients. Relevant duties concern staff qualifications, specimen identification, method validation, authorisation of results and quality standards. Genetic testing in healthcare may also engage Article 4 IVDR, including information about the nature and implications of testing and access to counselling for specified predispositions to conditions generally considered untreatable. If a hospital makes and uses its own assay, Article 5(5) IVDR calls for a separate assessment, including use within the health institution, no transfer of the device to another legal entity and an appropriate quality management system. Ordering a test online does not establish its regulatory status or the qualifications needed to interpret its result.<a href="#_ftn22" id="_ftnref22">[22]</a></p>



<h1 class="wp-block-heading">Human samples and the limits of biobanking</h1>



<p>The Polish Act on the Professions of Physician and Dentist treats research on biological material, including genetic material, taken from a person for scientific purposes as a medical experiment (Article 21(4)). Article 29a(2) deals separately with collection, processing, storage and distribution of material for scientific purposes. These biobanking activities are excluded from the definition. A biobank may thus preserve a sample under its procedures, while a subsequent project testing a specific hypothesis on that sample may require a favourable bioethics opinion, consent and insurance. Under this Polish regime a research experiment in a healthy or ill person may entail at most minimal risk proportionate to its potential scientific benefit. Article 23a excludes, among others, persons subject to a legal incapacitation order from such research experiments. These national conditions are distinct from the rules specific to medicinal product and device studies.<a href="#_ftn23" id="_ftnref23">[23]</a></p>



<p>Consider two plasma specimens stored in the same freezer. The first was drawn to establish an ageing research cohort and can be linked to its donor. The second is an anonymous remnant of routine diagnosis. In its TRANSMED guidance, the Polish Medical Research Agency distinguishes the original purpose of collection, the investigator’s access to the key and subsequent use of data in a clinical trial. These are practical pointers for assessing an individual project. Placing material in a biobank does not confer rights to carry out every future analysis. Article 28 of the Polish Act provides a particular route for scientific use of information from a medical experiment or screening where identification is impossible. That provision addresses information.<a href="#_ftn24" id="_ftnref24">[24]</a></p>



<p>Under Article 24(2)(7), participants in a medical experiment must be informed about foreseeable further use of results, data and material, including commercial use. For a sample bank, the practical decisions are whether new markers can be assayed, whether a specimen can be sent abroad, whether donors can be recontacted and whether an incidental finding with possible health implications will be returned. A research observation may first require clinical confirmation. The participant also needs a meaningful account of what withdrawal entails if material is still held, has been consumed in testing or has already contributed to aggregate results.<a href="#_ftn25" id="_ftnref25">[25]</a></p>



<p>In findings published on 22 October 2026, Poland’s Supreme Audit Office described genetic samples being sent to foreign laboratories without patients’ knowledge or consent. In a multicentre project, a material transfer agreement should identify the specimens and recipients, permitted analyses, conditions for onward transfer, return or destruction, and responsibility for breaching those limits. The parties must also establish the sender’s authority and check that the proposed transfer is consistent with what the donor was told. A signed agreement between institutions cannot supply permissions that neither institution holds.<a href="#_ftn26" id="_ftnref26">[26]</a></p>



<h1 class="wp-block-heading">Participant data and access to European cohorts</h1>



<p>A clock score linked to a participant may reveal information about present or future health. DNA analysis can also entail processing genetic data. The controller must identify each purpose and the relevant lawful basis under Article 6 and condition under Article 9(2) GDPR. Reliance on the scientific research condition in Article 9(2)(j) requires a basis in Union or Member State law and safeguards under Article 89. Coding limits the visibility of a participant’s identity. Where reidentification remains reasonably possible, the data remain protected. This matters when rare variants are combined with age, clinical history or a small recruitment site.<a href="#_ftn27" id="_ftnref27">[27]</a></p>



<p>The European Data Protection Board distinguishes informed consent to trial participation from the legal basis for processing personal data. The sponsor’s duties to ensure safety and reliability serve a different purpose from scientific analysis. Withdrawal ends further interventions covered by the participant’s decision, but does not automatically remove data already lawfully obtained. Article 58 CTR requires archiving of the trial master file for at least 25 years after the end of the trial, subject to any longer Union requirements. This period does not determine how long every specimen is to be retained. Article 28(2) CTR allows a separate request for consent to use data outside the protocol exclusively for scientific purposes.<a href="#_ftn28" id="_ftnref28">[28]</a></p>



<p>Access to the source records raises a further issue. Article 26(4) of Poland’s Act on Patients’ Rights permits disclosure of medical records to a higher education institution or research institute for scientific purposes without revealing information that identifies an individual. A company working with the university needs its own basis for access. Consortium partners should identify actual controller and processor roles, access to the key and all recipients. Processing likely to entail a high risk requires a data protection impact assessment. A transfer to a recipient outside the European Economic Area engages Chapter V GDPR.<a href="#_ftn29" id="_ftnref29">[29]</a></p>



<p>The European Health Data Space (EHDS) will facilitate secondary access to data. Most of Chapter IV will apply from 26 March 2029. Article 51(1)(q) covers data from biobanks, while the date for genetic, epigenomic and genomic data under point (f) is 26 March 2031. An applicant will need to specify the categories and a permitted purpose. If a biobank holds both clinical observations and genomic data, the two elements of the requested dataset need to be classified separately. The Regulation provides for data permits, a secure processing environment, an opt-out and a ban on use for advertising. To obtain pseudonymised data, a researcher must justify why anonymous data would not achieve the purpose. In 2026, citing the EHDS provides no immediate entitlement to a Polish cohort or to physical specimens.<a href="#_ftn30" id="_ftnref30">[30]</a></p>



<h1 class="wp-block-heading">Who can use the results and seek patent protection</h1>



<p>A joint university and biotechnology project needs to establish what each party brings to the research and what rights it can acquire. A laboratory may control the assay technique, a university the model code and a hospital the records and specimens entrusted to it for a limited purpose. A licence to use an algorithm alone confers no right to train it on another cohort, disclose data to an investor or submit them to a medicines authority. Rights to material and data must therefore be distinguished from rights to software and inventions, and from publication arrangements. The allocation should also allow the records needed for regulatory verification to be retained and made available.</p>



<p>Articles 5 and 6 of the Polish Clinical Trials Act impose a particular constraint. Under the ordinary definition of a non-commercial trial, the sponsor and any co-sponsors must fall within the statutory categories, which include universities, healthcare entities and investigators. The right to dispose of the trial data must belong exclusively to those entities. Article 5(1), point 3, excludes from this route trials undertaken as part of the scientific advice specified there or as part of a paediatric investigation plan. Article 6(1) restricts use of data to secure a marketing authorisation, to vary an authorisation or for marketing. It makes an exception for variations concerning the safety of the medicinal product. Article 6(2) and (3) prohibit transactions by the sponsor that enable the uses set out there and make contrary transactions void by operation of law.<a href="#_ftn31" id="_ftnref31">[31]</a></p>



<p>Article 6(4) disapplies paragraphs 1–3 to trials within Article 5(2). Such trials must be funded entirely from public funds and meet at least the requirements relating to eligible sponsors and control of the data. The mere existence of a grant therefore calls for further enquiry into the full budget, partner contributions and contractual terms. Article 7 permits free or discounted supply of the study medicine and scientific, technical or financial support from a manufacturer or marketing authorisation holder, provided the support is disclosed in the application and the relevant authorisation is obtained. Disclosure of such support does not in itself give that partner a right to use the data for registration. This matters when an investor seeks an option over the results before enrolment begins.<a href="#_ftn32" id="_ftnref32">[32]</a></p>



<p>For patent purposes, the discovery of a biological relationship must be distinguished from its technical application. A reagent kit, a new method of analysing a sample ex vivo or a defined further medical use of a known substance may be assessed. Novelty, inventive step and industrial application matter. For diagnostic methods, much turns on how the claims are framed and whether they encompass the required steps of diagnosis practised on the body. Publication disclosing the invention before a filing can destroy novelty. Consortium terms should allow time for filing while preserving the obligation to make trial results public.<a href="#_ftn33" id="_ftnref33">[33]</a></p>



<h1 class="wp-block-heading">Communicating a result within the limits of the evidence</h1>



<p>A participant report, a scientific abstract and a retail advertisement may cite the same number, but they invite different inferences. A paper can report the change on a named clock, a confidence interval, the comparator and disagreement between prespecified measures. On a package or sales page, “reverses ageing by three years” will ordinarily be understood as a statement about what the product does to a person. A footnote linking to a paper still leaves the advertiser to establish that the evidence supports the claim and that the advertising rules for the product permit it.</p>



<p>Polish Pharmaceutical Law prohibits, among other things, advertising medicines that are not authorised in Poland, using claims inconsistent with the summary of product characteristics in medicines advertising, and advertising prescription-only medicines to the public. For a test, Article 7 IVDR prohibits attributing functions or performance the device does not possess or suggesting uses outside the purpose covered by the conformity assessment. The Polish Medical Devices Act also requires public advertising to be understandable to a layperson and restricts public advertising of devices intended for professional users. It therefore matters whether a test campaign is directed to laboratories, prescribers or consumers.<a href="#_ftn34" id="_ftnref34">[34]</a></p>



<p>Food supplements are subject to EU health claims rules. A reference to general, non-specific health benefits must be accompanied by an authorised specific claim under Article 10(3) of Regulation (EC) No 1924/2006. As a rule, food information must not attribute disease prevention, treatment or cure to food. Claims about reducing a disease risk factor have a separate authorisation route under Article 14. For a new ingredient, the questions include whether it falls within a category in Article 3(2)(a) of Regulation (EU) 2015/2283, whether it was consumed to a significant degree in the EU before 15 May 1997, whether novel food authorisation is required and which conditions apply to its listing. Polish notification to the Chief Sanitary Inspector on first marketing a supplement is a market monitoring measure. It does not establish an anti-ageing effect.<a href="#_ftn35" id="_ftnref35">[35]</a></p>



<p>The practical value of an ageing biomarker is that a clinical question can be investigated before a distant patient outcome can be observed. In the opening example, a first paper can accurately report the difference in the clock score against the control. Using that score to decide who receives treatment requires validation of the test and the applicable regulatory route. Claiming that the therapy prolongs independent living requires evidence connecting its effect on the score with precisely that benefit. These decisions can be made in sequence. A programme designed on that basis preserves the value of the first observation while making clear what must be demonstrated next.</p>



<p data-pm-slice="1 1 []">KG LEGAL KIELTYKA GLADKOWSKI advises international life sciences and biotechnology businesses on Polish and EU regulatory requirements, research arrangements and commercialisation. Recognised by The Legal 500 for Healthcare and Life Sciences and Data Privacy and Data Protection, our firm combines sector knowledge with experience in corporate matters, negotiations and disputes.</p>
<p>We support projects where clinical research, technology and sensitive data intersect, helping clients address the legal requirements relevant to their research activities and business operations in Poland.</p>
<p>Contact: <a href="mailto:office@kg-legal.pl">office@kg-legal.pl</a></p>
<p>#LifeSciencesLaw #Biotechnology #ClinicalResearch #DataProtection #PolishLaw #KGLegal</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf">ICH E9</a>, Statistical Principles for Clinical Trials, section 2.2.6 (surrogate variables), EMA.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://doi.org/10.1016/j.ebiom.2019.08.069">L.J. Hickson et al.</a>, Senolytics decrease senescent cells in humans, EBioMedicine 47 (2019), pp. 446–456.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://eic.ec.europa.eu/system/files/2025-11/EIC-Work-Programme-2026.pdf">European Innovation Council</a>, EIC Work Programme 2026, section II.2.2, Biotechnology for Healthy Ageing, objective 2.</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf">ICH E9</a>, Statistical Principles for Clinical Trials, section 2.2.6 (surrogate variables), EMA.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://doi.org/10.1038/s43587-022-00357-y">R. Waziry et al.</a>, Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial, Nature Aging 3 (2023), pp. 248–257.&nbsp; <a href="https://doi.org/10.1038/s41591-026-04562-9">R. Sehgal et al.</a>, Responsiveness of epigenetic aging biomarkers to longevity interventions in humans, Nature Medicine 32 (2026), pp. 3477–3490.</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf">ICH E9(R1)</a>, Addendum on Estimands and Sensitivity Analysis in Clinical Trials, sections A.3–A.5, EMA.</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://www.ema.europa.eu/system/files/documents/regulatory-procedural-guideline/qualification-novel-methodologies-qonm-medicinal-product-development_en.pdf">EMA, Qualification of</a> novel methodologies for medicinal product development, procedural guidance for applicants, rev. 6 (2026).&nbsp; <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance">EMA, Scientific advice</a> and protocol assistance.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101">Directive 2001/83/EC on</a> the Community code relating to medicinal products for human use, Articles 1(2) and 2(2).&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/612/ogl">Polish Pharmaceutical Law Act of 6 September 2001</a>, Article 2 point 32 and Article 3a, consolidated text, Journal of Laws 2026, item 612, as amended.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62007CJ0140">CJEU</a>, Hecht-Pharma, C-140/07, judgment of 15 January 2009, EU:C:2009:5, paras 29, 32 and 39–42.</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a>&nbsp;&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101">Directive 2001/83/EC</a>, Articles 6, 8 and 26.&nbsp; <a href="https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/variations-including-extensions-marketing-authorisations/extensions-marketing-authorisations-questions-answers">EMA, Extensions of</a> marketing authorisations: questions and answers, question 1.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">Regulation (EU) No</a> 536/2014 on clinical trials on medicinal products for human use (CTR), Articles 1 and 2(2), points 1–4.</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">CTR, Article 2(2),</a> point 3.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32010L0063">Directive 2010/63/EU on</a> the protection of animals used for scientific purposes, Articles 4, 36 and 38.&nbsp; <a href="https://eli.gov.pl/eli/DU/2015/266/ogl">Polish Act of</a> 15 January 2015 on the Protection of Animals Used for Scientific or Educational Purposes, Articles 3a and 42.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">CTR, Articles 4–8</a> and Annex I.&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/2/ogl/pol">Polish Act of</a> 9 March 2023 on Clinical Trials of Medicinal Products for Human Use, Articles 9 and 21–25, consolidated text, Journal of Laws 2026, item 2.</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a>&nbsp;&nbsp;&nbsp; <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical-trials-first-version_en.pdf">EMA/CHMP</a>, Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials, EMA/CHMP/778709/2015, 9 January 2018, sections 5–6.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">CTR, Articles 28–31</a> and Annex I.</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a>&nbsp;&nbsp;&nbsp; <a href="https://pubmed.ncbi.nlm.nih.gov/40147475/">M.D. Witham et al.</a>, Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT), The Lancet Healthy Longevity 6 (2025), 100695.</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">CTR, Articles 31,</a> 37, 41–43 and Annex V.&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/2/ogl/pol">Polish Clinical Trials Act</a>, Articles 39–44.</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746">Regulation (EU) 2017/746</a> on in vitro diagnostic medical devices (IVDR), Articles 1(3)(a) and 2, points 2 and 12.&nbsp; <a href="https://health.ec.europa.eu/system/files/2022-05/mdcg_2022-10_en.pdf">MDCG 2022-10</a>, Q&amp;A on the interface between the CTR and the IVDR, May 2022, questions 5–7 and figure 1.</p>



<p><a href="#_ftnref17" id="_ftn17">[17]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746">IVDR</a>, Article 2 point 7 and Article 48, Annex VIII, rule 3(f), and Annex IX, section 5.2.&nbsp; <a href="https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices/companion-diagnostics-vitro-diagnostics">EMA, Companion diagnostics</a> (in vitro diagnostics).</p>



<p><a href="#_ftnref18" id="_ftn18">[18]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746">IVDR</a>, Articles 56–58 and Annex XIII. See also MDCG 2022-10, question 7.</p>



<p><a href="#_ftnref19" id="_ftn19">[19]</a>&nbsp;&nbsp;&nbsp; <a href="https://www.gov.pl/web/urpl/badania-dzialania-wyrobow-medycznych-do-diagnostyki-in-vitro">URPL</a>, Performance studies of in vitro diagnostic medical devices (in Polish). See also the Polish Act of 7 April 2022 on Medical Devices, consolidated text, Journal of Laws 2024, item 1620, as amended.&nbsp; <a href="https://www.gov.pl/web/urpl/pytaniaiodpowiedzi">URPL</a>, Questions and answers, questions 4–5 on combined studies (in Polish).&nbsp; <a href="https://health.ec.europa.eu/document/download/183eb4ee-d093-4a6a-bf18-fa04a744448e_en?filename=md_combine_comb-proj1_sponsor-guide-phase2_en.pdf">European Commission</a>, COMBINE Project 1, phase two sponsor guide, sections 1–2 and Annex I.</p>



<p><a href="#_ftnref20" id="_ftn20">[20]</a>&nbsp;&nbsp;&nbsp; <a href="https://health.ec.europa.eu/document/download/b45335c5-1679-4c71-a91c-fc7a4d37f12b_en?filename=md_mdcg_2019_11_guidance_qualification_classification_software_en.pdf">MDCG 2019-11 rev. 1</a>, Guidance on Qualification and Classification of Software, June 2025.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745">Regulation (EU) 2017/745 (MDR)</a>, Article 2 point 1 and Annex VIII, rule 11. See also IVDR, Article 2 point 2.</p>



<p><a href="#_ftnref21" id="_ftn21">[21]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689">Regulation (EU) 2024/1689 (AI Act)</a>, Articles 2(6) and (8), 3(1) and 6(1), and Annex I.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32026R1744">Regulation (EU) 2026/1744 (Digital Omnibus on AI)</a>, amendment to Article 113 of the AI Act, recital 38.</p>



<p><a href="#_ftnref22" id="_ftn22">[22]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2025/1295/ogl">Polish Act of</a> 15 September 2022 on Laboratory Medicine, consolidated text, Journal of Laws 2025, item 1295, as amended.&nbsp; <a href="https://eli.gov.pl/eli/DU/2025/961/ogl/pol">Polish Minister of</a> Health Regulation of 30 June 2025 on laboratory quality standards, Journal of Laws 2025, item 961, Annex 3.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746">IVDR</a>, Article 4, in particular paragraphs 2–3.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746">IVDR</a>, Article 5(5), in particular points (a)–(c).</p>



<p><a href="#_ftnref23" id="_ftn23">[23]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/37/ogl/pol">Polish Act of</a> 5 December 1996 on the Professions of Physician and Dentist, Articles 21, 23, 23a, 23c, 25, 29 and 29a, consolidated text, Journal of Laws 2026, item 37, as amended.</p>



<p><a href="#_ftnref24" id="_ftn24">[24]</a>&nbsp;&nbsp;&nbsp; <a href="https://abm.gov.pl/download/1/9242/OdpowiedzinapytaniazczatuwebinariumTransmedI.pdf">Polish Medical Research Agency</a>, TRANSMED I webinar answers (ABM/2024/8), p. 1, archived and coded specimens (in Polish).&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/37/ogl/pol">Polish Act on</a> the Professions of Physician and Dentist, Article 24(2), points 5 and 7, and Articles 25 and 28.</p>



<p><a href="#_ftnref25" id="_ftn25">[25]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/37/ogl/pol">Polish Act on</a> the Professions of Physician and Dentist, Article 24(2), points 5 and 7, and Articles 25 and 28.</p>



<p><a href="#_ftnref26" id="_ftn26">[26]</a>&nbsp;&nbsp;&nbsp; <a href="https://www.nik.gov.pl/komunikaty/badania-genetyczne-moga-zmienic-zycie-calej-rodziny-panstwo-od-lat-nie-ustalilo-kompleksowych-zasad-ochrony-materialu-genetycznego">Polish Supreme Audit Office (NIK)</a>, findings on genetic testing and safeguards for genetic material, 22 October 2026 (in Polish).</p>



<p><a href="#_ftnref27" id="_ftn27">[27]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679">Regulation (EU) 2016/679 (GDPR)</a>, Article 4, points 5, 13 and 15, Articles 5, 6, 9 and 89, and recital 26.</p>



<p><a href="#_ftnref28" id="_ftn28">[28]</a>&nbsp;&nbsp;&nbsp; <a href="https://www.edpb.europa.eu/documents/legislative-opinion/opinion-32019-concerning-the-questions-and-answers-on-the-interplay_en">EDPB</a>, Opinion 3/2019 on the interplay between the CTR and the GDPR, 23 January 2019, sections 2–3.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536">CTR, Articles 28(2)–(3)</a> and 58.</p>



<p><a href="#_ftnref29" id="_ftn29">[29]</a>&nbsp;&nbsp;&nbsp; <a href="https://api.sejm.gov.pl/eli/acts/DU/2024/581/text.html">Polish Act of</a> 6 November 2008 on Patients’ Rights and the Commissioner for Patients’ Rights, Article 26(4), consolidated text, Journal of Laws 2024, item 581, as amended.&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679">GDPR</a>, Articles 26, 28, 32 and 35, and Chapter V.</p>



<p><a href="#_ftnref30" id="_ftn30">[30]</a>&nbsp;&nbsp;&nbsp; <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32025R0327">Regulation (EU) 2025/327</a> on the European Health Data Space, Articles 51, 53–54, 66, 68, 71, 73 and 105.</p>



<p><a href="#_ftnref31" id="_ftn31">[31]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/2/ogl/pol">Polish Clinical Trials Act</a>, Articles 5(1) and 6(1)–(3).</p>



<p><a href="#_ftnref32" id="_ftn32">[32]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/2/ogl/pol">Polish Clinical Trials Act</a>, Articles 5(2), 6(4) and 7.</p>



<p><a href="#_ftnref33" id="_ftn33">[33]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/api/acts/DU/2023/1170/text.html">Polish Industrial Property Act of 30 June 2000</a>, Articles 24–29, consolidated text, Journal of Laws 2023, item 1170, as amended.&nbsp; <a href="https://www.epo.org/en/legal/guidelines-epc/2026/g_ii_4_2_1_3.html">European Patent Office</a>, Guidelines for Examination 2026, G-II, 4.2.1.3, referring to G 1/04 and Article 53(c) of the European Patent Convention.&nbsp; <a href="https://www.epo.org/en/legal/guidelines-epc/2026/g_vi_6_1.html">European Patent Office</a>, Guidelines for Examination 2026, G-VI, 6.1, Article 54(4)–(5) EPC.</p>



<p><a href="#_ftnref34" id="_ftn34">[34]</a>&nbsp;&nbsp;&nbsp; <a href="https://eli.gov.pl/eli/DU/2026/612/ogl">Polish Pharmaceutical Law</a>, Articles 52–57, in particular Articles 56 and 57(1).&nbsp; <a href="https://eli.gov.pl/eli/DU/2024/1620/ogl">Polish Medical Devices Act</a>, Articles 54–55, read with Article 7 IVDR.</p>



<p><a id="_ftn35" href="#_ftnref35">[35]</a>    <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32006R1924">Regulation (EC) No</a> 1924/2006 on nutrition and health claims made on foods, Articles 2, 10 and 14.  <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32011R1169">Regulation (EU) No</a> 1169/2011 on food information to consumers, Article 7(3)–(4).  <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32015R2283">Regulation (EU) 2015/2283 on novel foods</a>, Articles 3, 6 and 10.  <a href="https://eli.gov.pl/eli/DU/2026/1399/ogl">Polish Food and</a> Nutrition Safety Act of 25 August 2006, Article 29, consolidated text, Journal of Laws 2026, item 1399.</p>
<p> </p>



<div class="wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex"></div>






<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/ageing-biomarkers-as-evidence-of-geroprotective-efficacy/">Ageing biomarkers as evidence of geroprotective efficacy</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/ageing-biomarkers-as-evidence-of-geroprotective-efficacy/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 15 Sep 2026 19:35:31 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[EU Regulatory Law]]></category>
		<category><![CDATA[European Health Data Space]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[Health Claims]]></category>
		<category><![CDATA[health tech]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Longevity Industry]]></category>
		<category><![CDATA[Longevity Washing]]></category>
		<category><![CDATA[Medical Devices Regulation]]></category>
		<category><![CDATA[Novel Foods]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8913</guid>

					<description><![CDATA[<p>Publication date: September 15, 2026 ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL I. Introduction The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color"><strong>Publication date: September 15, 2026</strong></mark></p>



<figure class="wp-block-video"><video controls src="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4"></video></figure>



<p class="has-luminous-vivid-amber-background-color has-background has-large-font-size">ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL</p>



<span id="more-8913"></span>



<p class="has-medium-font-size">I. Introduction</p>



<p>The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.<a href="#_ftn1" id="_ftnref1">[1]</a> Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.</p>



<p>The gap between an enormous market and a non-existent legal definition is precisely where legal risk accumulates. Where there is no definition, there is classification risk, claims risk, and enforcement risk. There is also a phenomenon that this article, borrowing from the vocabulary of environmental marketing, calls “longevity washing.”</p>



<p>This article examines the longevity industry through the lens of EU regulatory law. The EU framework governs a market of some 450 million consumers and, because it is horizontal, sector-specific, and increasingly enforcement-oriented, it offers a useful point of comparison for practitioners in the United States, Asia, and Latin America. Part II explains why “longevity” is not a legal category and introduces the borderline-product problem that follows from that fact. Part III develops the concept of longevity washing and its consumer-facing, unfair-commercial-practice, and investor-facing dimensions. Part IV addresses the regulation of artificial intelligence in longevity research and diagnostics, including the revised timeline of the AI Act, the position of the European Medicines Agency on AI in the medicinal-product lifecycle, and the data-protection architecture formed by the GDPR and the European Health Data Space. Part V maps the sectoral “hot spots” across pharmaceuticals, medical devices, cosmetics, and food supplements. Part VI draws conclusions for practitioners.</p>



<h3 class="wp-block-heading">II. “Longevity” in the Eyes of the Law: The Borderline-Product Problem</h3>



<p>In EU regulatory law, aging is not a disease. The European Medicines Agency has never approved a medicinal product with “aging” as a therapeutic indication, and under Directive 2001/83/EC a medicinal product is defined by reference to the treatment or prevention of disease or the restoration, correction, or modification of physiological functions.<a href="#_ftn2" id="_ftnref2">[2]</a> The position in the United States is comparable. The long-running debate around the Targeting Aging with Metformin (TAME) trial illustrates the point: its designers had to negotiate a trial protocol with the Food and Drug Administration that targets aging indirectly, through a composite of age-related diseases, precisely because “aging” itself is not an approvable indication.<a href="#_ftn3" id="_ftnref3">[3]</a></p>



<p>The consequence is profound. A company cannot lawfully market a product “to treat aging.” The entire longevity industry therefore operates in the space of indirect claims: “supports healthy aging,” “promotes cellular health,” “extends healthspan.” Each of those phrases pushes the product toward one of several very different regulatory regimes.</p>



<p>This is the borderline-product problem, and it is the single most important legal concept in the sector. The same molecule – an NAD precursor, for example – may be: a medicinal product, if it is presented as treating or preventing disease or exerts a significant pharmacological, immunological, or metabolic effect; a food supplement under Directive 2002/46/EC;<a href="#_ftn4" id="_ftnref4">[4]</a> a novel food requiring pre-market authorisation under Regulation (EU) 2015/2283;<a href="#_ftn5" id="_ftnref5">[5]</a> a cosmetic under Regulation (EC) No 1223/2009, if applied to the skin with a claim limited to appearance;<a href="#_ftn6" id="_ftnref6">[6]</a> or a medical device. The last category is broader than it may appear: since the Medical Device Regulation (MDR) came into application, products listed in its Annex XVI – dermal fillers, certain energy-based aesthetic equipment – are regulated as devices even where they have no medical purpose at all.<a href="#_ftn7" id="_ftnref7">[7]</a></p>



<p>Classification does not follow the label a company chooses. It follows presentation, composition, and route of administration. The Court of Justice of the European Union has held for four decades that a product is a medicinal product “by presentation” where it is described or recommended as having properties for treating or preventing disease, irrespective of whether it actually has those properties; and that classification “by function” turns on a case-by-case scientific assessment of the product’s actual pharmacological, immunological, or metabolic action, not on the manufacturer’s intention.<a href="#_ftn8" id="_ftnref8">[8]</a> Marketing language alone can therefore reclassify a product and, with it, the entire compliance burden: marketing authorisation, good manufacturing practice, pharmacovigilance, and advertising restrictions.</p>



<p>When a client says “we are a longevity company,” the first question counsel should ask is: <em>which regime are you actually in?</em> “Longevity” is a marketing word. The law knows only medicines, devices, foods, and cosmetics.</p>



<h3 class="wp-block-heading">III. Longevity Washing: When the Claim Outruns the Science</h3>



<p>Greenwashing – claiming environmental virtue one does not have – is a familiar concept. Longevity washing is its younger sibling: labelling a product, a clinic, a research programme, or an entire company as “longevity-focused” when the science, the indication, or the business model does not support that description. The practice matters legally for three reasons.</p>



<h2 class="wp-block-heading"><em>A. Consumer-Facing Claims</em></h2>



<p>Under the Health Claims Regulation, any health claim made on a food – and food supplements are foods – must be specifically authorised and listed in the EU register.<a href="#_ftn9" id="_ftnref9">[9]</a> Claims such as “slows aging,” “supports cellular repair,” or “extends lifespan” are not authorised health claims. National authorities in the EU and the United Kingdom have treated phrases such as “cellular repair” and even “healthy aging” as impermissible where they imply a physiological mechanism or a reduction of disease risk. A substantial part of the longevity supplement market is thus operating with claims that would not survive enforcement scrutiny.</p>



<h2 class="wp-block-heading"><em>B. Unfair Commercial Practices and the Greenwashing Template</em></h2>



<p>The second layer is the general prohibition of misleading commercial practices under the Unfair Commercial Practices Directive (UCPD).<a href="#_ftn10" id="_ftnref10">[10]</a> Here the EU has recently built an entire enforcement architecture against greenwashing that repays close study by anyone advising on health claims. The Empowering Consumers for the Green Transition Directive amends the UCPD to prohibit generic environmental claims – “eco-friendly,” “climate-neutral” – unless the trader can demonstrate recognised excellent environmental performance, and it adds a series of specific greenwashing practices to the UCPD’s blacklist. Its provisions apply across the Union from 27 September 2026.<a href="#_ftn11" id="_ftnref11">[11]</a></p>



<p>The Directive should be read as a template. If “climate-neutral” now requires substantiation, it is a very short doctrinal step for regulators and courts to demand the same of “clinically proven to slow biological aging.” The methodology of anti-greenwashing enforcement – generic claim, absence of substantiation, misleading omission – maps directly onto longevity claims. The UCPD’s general clauses on misleading actions and omissions already provide the legal basis; what the green-claims reform supplies is a worked example of how those clauses can be operationalised against vague virtue-signalling.</p>



<h2 class="wp-block-heading"><em>C. Investor-Facing Washing</em></h2>



<p>The third dimension is of particular relevance to transactional lawyers. Start-ups increasingly brand themselves as “longevity biotech” because that is where the capital is, even when the underlying asset is a conventional dermatology product or a wellness application. For investors, this creates due-diligence risk: is the “longevity platform” in fact a regulated medicinal pipeline, with all the timeline and cost that implies, or a supplement business one enforcement letter away from relabelling? Misclassification discovered after investment is a valuation event. For the company, aggressive longevity framing in fundraising materials can generate liability under securities and misrepresentation rules in multiple jurisdictions. In due diligence on a longevity start-up, the regulatory classification memorandum is not an annex to the deal; it <em>is</em> the deal.</p>



<h3 class="wp-block-heading">IV. Artificial Intelligence in Longevity Research and Diagnostics</h3>



<p>The longevity field is arguably the most AI-dependent sector in the life sciences, for a simple reason: aging is not one target but thousands of interacting biological processes. A geroprotective drug cannot be designed the way an antibiotic is designed. The entire aging phenotype must be modelled, and that means machine learning on large multi-omic datasets. AI is not an add-on in longevity; it is the core methodology. That raises three distinct regulatory questions under EU law.</p>



<h2 class="wp-block-heading"><em>A. The AI Act</em></h2>



<p>Regulation (EU) 2024/1689, the AI Act, is the most comprehensive horizontal AI regulation in force anywhere and applies to almost every AI system used in the longevity value chain.<a href="#_ftn12" id="_ftnref12">[12]</a> It adopts a risk-based structure – prohibited practices, high-risk systems, transparency obligations, and minimal-risk systems – and the critical category for this sector is high-risk. An AI system that is itself a medical device, or a safety component of one, under the MDR or the In Vitro Diagnostic Regulation, and that is subject to third-party conformity assessment under those instruments, is high-risk under Article 6(1) and Annex I of the AI Act.<a href="#_ftn13" id="_ftnref13">[13]</a> This captures, for example, an AI tool that estimates a patient’s “biological age” from a blood panel and uses that estimate to guide a clinical intervention; an AI-driven diagnostic that predicts age-related disease risk; and the software layer of many longevity-clinic platforms once it makes a diagnostic or prognostic claim.</p>



<p>High-risk status is not a prohibition; it is a compliance regime. It requires a risk-management system, data governance with representative and bias-tested training data, technical documentation, logging, human oversight, transparency to deployers, accuracy, robustness and cybersecurity, a conformity assessment, and post-market monitoring.<a href="#_ftn14" id="_ftnref14">[14]</a> For most longevity start-ups this is a wholly new compliance layer on top of MDR conformity assessment, and the two must be coordinated.</p>



<p>The timeline has recently changed, and practitioners should update their advice accordingly. The original AI Act applied the high-risk obligations from 2 August 2026 for stand-alone systems listed in Annex III and from 2 August 2027 for AI embedded in products covered by Annex I, including medical devices. The Digital Omnibus on AI, adopted as Regulation (EU) 2026/1744 and in force since 27 July 2026, defers those dates to 2 December 2027 and 2 August 2028 respectively.<a href="#_ftn15" id="_ftnref15">[15]</a> The deferral does not lighten the substantive regime; the prohibitions in Article 5, the obligations of providers of general-purpose AI models, and the transparency obligations of Article 50 (which apply from 2 August 2026) are unaffected. For longevity companies whose AI is a medical device, the practical effect is a compliance window of roughly two years, during which harmonised standards and notified-body capacity are expected to mature. The window is an opportunity to design AI Act compliance into the MDR technical file from the outset rather than to defer the exercise.</p>



<h2 class="wp-block-heading"><em>B. AI in Drug Discovery and the European Medicines Agency</em></h2>



<p>The position for drug discovery is more nuanced. An AI model used purely internally to identify candidate molecules – the classic “AI for drug discovery” use case that dominates longevity-biotech pitch decks – is generally not, in itself, a high-risk AI system under the AI Act, because it does not make or materially influence decisions about individual patients. The regulatory question shifts instead to the European Medicines Agency. The EMA’s Reflection Paper on the use of AI in the medicinal product lifecycle sets out the Agency’s expectations from discovery through pharmacovigilance.<a href="#_ftn16" id="_ftnref16">[16]</a> Its core message is that the burden of proof rests on the sponsor to demonstrate that the AI model is fit for its regulatory purpose. That entails documented data provenance, model validation, a degree of explainability appropriate to the stage of development, and lifecycle management of the model itself.</p>



<p>If a longevity company tells its investors that “our AI discovered this molecule,” the regulator will eventually ask to see the model, the training data, and the validation. Vague AI claims in fundraising materials do not survive regulatory scrutiny and, increasingly, do not survive investor due diligence either.</p>



<h2 class="wp-block-heading"><em>C. Data: The GDPR and the European Health Data Space</em></h2>



<p>The third question concerns data, and it is here that longevity becomes uniquely difficult. Aging research is inherently longitudinal and multi-omic: genomic, epigenetic, and proteomic data, wearable data, and medical records, ideally across decades. Under the General Data Protection Regulation this is special-category data – health, genetic, and biometric data – and the available lawful bases are narrow.<a href="#_ftn17" id="_ftnref17">[17]</a> The scientific-research provisions of Article 9(2)(j) and Article 89 assist, but they are implemented differently in each Member State, which produces real fragmentation for pan-European longevity cohorts.</p>



<p>The European Health Data Space Regulation adds a second layer.<a id="_ftnref18" href="#_ftn18">[18]</a> It creates, for the first time, a mandatory EU-wide framework for the secondary use of electronic health data, administered by health-data-access bodies in each Member State. For longevity research the EHDS is potentially transformative, because it opens access to population-scale health data for research purposes. It also imposes strict conditions: purpose limitation, processing only within secure processing environments, a prohibition on re-identification, and specific prohibitions on using the data for advertising or marketing, for decisions detrimental to individuals such as insurance or employment decisions, or for developing products harmful to health.<a id="_ftnref19" href="#_ftn19">[19]</a> The secondary-use chapter applies from March 2029 for most data categories, but the lead time is short in the context of longitudinal cohorts. Longevity companies that intend to monetise health data – and many do – should be mapping their data flows against the EHDS regime now.</p>



<h3 class="wp-block-heading">V. Sector-by-Sector Regulatory Hot Spots</h3>



<p>Four sectoral silos together make up the longevity industry, and the same start-up frequently straddles two or three of them without realising it. In each silo, specific “hot spots” – advertising, manufacturing standards, registration, and market withdrawal – recur in practice.</p>



<h2 class="wp-block-heading"><em>A. Pharmaceuticals</em></h2>



<p>True longevity drugs – rapamycin analogues, senolytics, geroprotectors – sit squarely within Directive 2001/83/EC and its implementing rules, and will continue to do so under the new pharmaceutical package once it applies. Three practical hot spots stand out. First, off-label prescribing of rapamycin and metformin for longevity indications is widespread in private clinics across Europe. Off-label prescribing as such is a matter of clinical freedom, but off-label <em>promotion</em> by or on behalf of the marketing-authorisation holder is prohibited: advertising must conform to the summary of product characteristics, and advertising of unauthorised products or indications is not permitted.<a href="#_ftn20" id="_ftnref20">[20]</a> Longevity clinics are increasingly the vehicle through which promotional messaging reaches patients, and enforcement authorities have begun to take notice. Second, good manufacturing practice: anything presented as a medicine must be manufactured under an EU manufacturing authorisation and EU GMP, with qualified persons and full traceability; compounding pharmacies producing “longevity peptides” have become a significant enforcement target. Third, unlicensed importation: a large part of the longevity-peptide market operates through personal importation and grey channels, and customs enforcement across the EU has visibly tightened.</p>



<h2 class="wp-block-heading"><em>B. Medical Devices</em></h2>



<p>The MDR has fundamentally reshaped this space. Aesthetic devices – dermal fillers, energy-based devices used in longevity clinics, at-home devices marketed for “cellular rejuvenation” – are caught by Annex XVI even without a medical purpose. Three hot spots follow. Classification: many longevity wearables and applications become software as a medical device once they make a diagnostic or prognostic claim. Advertising: Article 7 of the MDR prohibits misleading claims and specifically prohibits ascribing to a device functions and properties it does not have, which operates in practice as a codified anti-washing rule for devices.<a href="#_ftn21" id="_ftnref21">[21]</a> Registration and vigilance: the first four modules of the EUDAMED database – actor registration, UDI/device registration, notified bodies and certificates, and market surveillance – have been mandatory since 28 May 2026, with legacy devices to be registered by 28 November 2026; the vigilance module is not yet mandatory, so serious incidents and field safety corrective actions continue to be reported to national competent authorities.<a href="#_ftn22" id="_ftnref22">[22]</a> Market withdrawals happen: a device sold as a “cellular biomarker analyser” without valid clinical evidence can be removed from the market by any national competent authority, and the MDR’s market-surveillance coordination means that one withdrawal can cascade across the Union.</p>



<h2 class="wp-block-heading"><em>C. Cosmetics and Aesthetic Products</em></h2>



<p>The Cosmetics Regulation governs anti-aging creams, serums, and topical actives. Two hot spots dominate. The first is the Product Information File: the responsible person must hold a complete file including a safety assessment and substantiation of every claim. The second is the Claims Regulation, Commission Regulation (EU) No 655/2013, with its six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making.<a href="#_ftn23" id="_ftnref23">[23]</a> A claim such as “reverses skin aging at the cellular level” fails the evidential-support criterion unless a robust dossier stands behind it. Enforcement is largely national, but the Cosmetic Products Notification Portal is EU-wide, and non-compliant products are routinely notified through the Safety Gate rapid-alert system.</p>



<h2 class="wp-block-heading"><em>D. Food Supplements and Novel Foods</em></h2>



<p>It is in the food and supplement space that the longevity industry is most creative and most exposed. Directive 2002/46/EC governs vitamins and minerals in supplements; everything else falls under the general food law of Regulation (EC) No 178/2002<a href="#_ftn24" id="_ftnref24">[24]</a> and, critically, the Novel Food Regulation. Nicotinamide mononucleotide (NMN), one of the most heavily marketed longevity molecules, is the paradigmatic case. NMN is treated as a novel food in the EU, which means it cannot lawfully be placed on the market as a supplement without pre-market authorisation by the Commission following an EFSA safety assessment. Nicotinamide riboside received such an authorisation in 2020.<a href="#_ftn25" id="_ftnref25">[25]</a> NMN has not – although the picture is now moving. In March 2026 EFSA’s NDA Panel adopted a positive opinion on the safety of β-NMN in food supplements at up to 300 mg per day for adults, and the opinion was published in May 2026.<a href="#_ftn26" id="_ftnref26">[26]</a> An EFSA opinion is a scientific assessment, not an authorisation; the Commission must still adopt an implementing act adding NMN to the Union list, and where the applicant has requested data protection the authorisation will initially be proprietary to that applicant’s specification. Until that act is adopted, NMN products on the shelves of European longevity clinics remain unauthorised novel foods. That is not a grey area; it is a non-compliant market operating in plain sight, and it is the kind of enforcement pipeline that eventually produces high-profile withdrawal actions. Once the Health Claims Regulation is added to the picture, the conclusion is unavoidable: the food and supplement leg of the longevity industry is the most legally exposed part of the entire sector.</p>



<h1 class="wp-block-heading">VI. Conclusions</h1>



<p>The longevity industry is a genuine scientific and commercial phenomenon, and much of the underlying research is serious. But lawyers advising companies, investors, clinicians, and, increasingly, regulators in this space must see it clearly: “longevity” is not a legal category. It is a marketing frame layered on top of four very different regulatory regimes. Three practical conclusions follow for anyone whose product touches European consumers.</p>



<p>First, always begin with classification. The word “longevity” conveys nothing about the applicable regime. Ask what the product is, how it is presented, and what it does, and let the regulatory regime follow from those answers.</p>



<p>Second, treat longevity claims the way green claims are now treated. The direction of enforcement is unmistakable. The Empowering Consumers for the Green Transition Directive, applicable from 27 September 2026, gives regulators a sharpened toolkit that will, sooner or later, be pointed at health and wellness claims. Substantiation is no longer optional.</p>



<p>Third, integrate AI Act compliance with sectoral compliance from the outset. For any longevity venture using AI in diagnostics or patient-facing decision support, the AI Act, the MDR, and the GDPR, soon joined by the European Health Data Space, form a single interlocking compliance architecture. The deferral of the AI Act’s high-risk obligations to 2027 and 2028 is a design window, not a reprieve. Retrofitting is expensive; designing for compliance is not.</p>



<p>The longevity industry will keep growing, and regulators will keep catching up. The lawyers who understand both the science and the sectoral map will be the ones clients call first.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a> Longevity economy estimates vary widely by definition; see, e.g., the periodic longevity-market reports of Bank of America Global Research and McKinsey Health Institute. The figure is offered here as an order of magnitude, not a precise valuation.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a> Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, art. 1(2), 2001 O.J. (L 311) 67 [hereinafter Directive 2001/83]. At the time of writing, the new EU pharmaceutical package (a new directive on the Union code for medicinal products for human use and a new regulation on Union authorisation procedures) has been politically agreed and is in the final stage of formal adoption; the substantive rules discussed here are carried over into the new framework, which will apply after a transitional period of approximately two years from entry into force.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a> See Nir Barzilai et al., Metformin as a Tool to Target Aging, 23 Cell Metabolism 1060 (2016) (describing the design of the Targeting Aging with Metformin (TAME) trial around a composite of age-related diseases).</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the Approximation of the Laws of the Member States Relating to Food Supplements, 2002 O.J. (L 183) 51.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a> Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on Novel Foods, 2015 O.J. (L 327) 1 [hereinafter Novel Food Regulation].</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a> Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on Cosmetic Products, 2009 O.J. (L 342) 59 [hereinafter Cosmetics Regulation].</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a> Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Annex XVI, 2017 O.J. (L 117) 1 [hereinafter MDR]; Commission Implementing Regulation (EU) 2022/2346 of 1 December 2022 Laying Down Common Specifications for the Groups of Products Without an Intended Medical Purpose Listed in Annex XVI, 2022 O.J. (L 311) 60.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a> Case 227/82, Van Bennekom, ECLI:EU:C:1983:354 (establishing that a product is a medicinal product “by presentation” where it is described or recommended as having therapeutic or prophylactic properties, irrespective of its actual efficacy); Case C-319/05, Comm’n v. Germany, ECLI:EU:C:2007:678 (garlic capsules); Case C-140/07, Hecht-Pharma GmbH v. Staatliches Gewerbeaufsichtsamt Luneburg, ECLI:EU:C:2009:5 (classification “by function” requires a case-by-case assessment of pharmacological, immunological or metabolic properties). See also Directive 2001/83, supra note 2, art. 2(2) (in cases of doubt, the medicinal-products regime prevails).</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a> Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on Nutrition and Health Claims Made on Foods, arts. 10, 13, 14, 2006 O.J. (L 404) 9 [hereinafter Health Claims Regulation]. The EU Register of nutrition and health claims is maintained by the European Commission.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a> Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 Concerning Unfair Business-to-Consumer Commercial Practices in the Internal Market, 2005 O.J. (L 149) 22 [hereinafter UCPD].</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a> Directive (EU) 2024/825 of the European Parliament and of the Council of 28 February 2024 Amending Directives 2005/29/EC and 2011/83/EU as Regards Empowering Consumers for the Green Transition, OJ L, 2024/825, 6.3.2024 [hereinafter ECGT Directive]. Member States were required to transpose the Directive by 27 March 2026; its provisions apply from 27 September 2026. The separate Green Claims Directive proposal, which would have introduced ex ante verification of explicit environmental claims, was withdrawn by the Commission in 2025 and is not discussed here.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a> Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 Laying Down Harmonised Rules on Artificial Intelligence, OJ L, 2024/1689, 12.7.2024 [hereinafter AI Act].</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a> AI Act, supra note 12, art. 6(1) &amp; Annex I, § A (listing the MDR and Regulation (EU) 2017/746 on in vitro diagnostic medical devices). The Annex I route applies where the AI system is a product, or a safety component of a product, that is itself subject to third-party conformity assessment under the listed Union harmonisation legislation.</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a> AI Act, supra note 12, arts. 9–15, 17, 43, 72.</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a> Regulation (EU) 2026/1744 of the European Parliament and of the Council Amending Regulation (EU) 2024/1689 as Regards the Simplification of Certain Obligations (“Digital Omnibus on AI”), OJ L, 2026/1744, 24.7.2026 (in force 27 July 2026). The Regulation defers the high-risk obligations for stand-alone (Annex III) systems to 2 December 2027 and for AI embedded in products covered by Annex I, including medical devices, to 2 August 2028; the Article 50 transparency obligations continue to apply from 2 August 2026.</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a> Eur. Medicines Agency, Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle, EMA/CHMP/CVMP/83833/2023 (adopted Sept. 2024).</p>



<p><a href="#_ftnref17" id="_ftn17">[17]</a> Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data, arts. 9(2)(j), 89, 2016 O.J. (L 119) 1 [hereinafter GDPR].</p>



<p><a href="#_ftnref18" id="_ftn18">[18]</a> Regulation (EU) 2025/327 of the European Parliament and of the Council of 11 February 2025 on the European Health Data Space, OJ L, 2025/327, 5.3.2025 [hereinafter EHDS Regulation]. The Regulation entered into force on 26 March 2025 and applies in stages: most provisions from 26 March 2027, and the core secondary-use chapter from 26 March 2029 (2031 for certain data categories). See id. art. 105.</p>



<p><a href="#_ftnref19" id="_ftn19">[19]</a> EHDS Regulation, supra note 18, arts. 50–54 (secure processing environments; permitted and prohibited purposes of secondary use).</p>



<p><a href="#_ftnref20" id="_ftn20">[20]</a> Directive 2001/83, supra note 2, art. 87(2) (all parts of advertising must comply with the particulars listed in the summary of product characteristics), arts. 40–53 (manufacturing authorisation and good manufacturing practice) and art. 87(1) (prohibition of advertising of medicinal products without a marketing authorisation).</p>



<p><a href="#_ftnref21" id="_ftn21">[21]</a> MDR, supra note 7, art. 7.</p>



<p><a href="#_ftnref22" id="_ftn22">[22]</a> Commission Decision (EU) 2025/2371 of 26 November 2025 (declaring the first four EUDAMED modules functional), OJ L, 2025/2371, 27.11.2025; Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024, OJ L, 2024/1860, 9.7.2024 (gradual roll-out of EUDAMED). The four modules (actor registration, UDI/device registration, notified bodies and certificates, market surveillance) are mandatory from 28 May 2026; legacy devices remaining on the market must be registered by 28 November 2026. The vigilance and clinical-investigation modules are not yet mandatory, and serious incidents continue to be reported to national competent authorities.</p>



<p><a href="#_ftnref23" id="_ftn23">[23]</a> Cosmetics Regulation, supra note 6, arts. 11, 13, 20; Commission Regulation (EU) No 655/2013 of 10 July 2013 Laying Down Common Criteria for the Justification of Claims Used in Relation to Cosmetic Products, Annex, 2013 O.J. (L 190) 31.</p>



<p><a href="#_ftnref24" id="_ftn24">[24]</a> Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 Laying Down the General Principles and Requirements of Food Law, 2002 O.J. (L 31) 1.</p>



<p><a href="#_ftnref25" id="_ftn25">[25]</a> Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 Authorising the Placing on the Market of Nicotinamide Riboside Chloride as a Novel Food, 2020 O.J. (L 7) 6.</p>



<p><a id="_ftn26" href="#_ftnref26">[26]</a> EFSA Panel on Nutrition, Novel Foods and Food Allergens, Safety of Beta-Nicotinamide Mononucleotide (β-NMN) Pursuant to Regulation (EU) 2015/2283 and the Bioavailability of Nicotinamide from This Source in the Context of Directive 2002/46/EC, 24 EFSA J. e10007 (2026) (opinion adopted 4 March 2026, published 11 May 2026). Authorisation requires a Commission implementing act amending the Union list established by Commission Implementing Regulation (EU) 2017/2470; at the time of writing no such act has been published, and any authorisation granted on the basis of proprietary data will initially benefit only the applicant. See Novel Food Regulation, supra note 5, arts. 12, 26.</p>
<p> </p>



<p>#LongevityIndustry #LongevityWashing #EURegulatoryLaw #ArtificialIntelligence #AIAct #HealthcareLaw #LifeSciencesLaw #HealthTech #MedicalDevices #PharmaceuticalLaw #GDPR #EuropeanHealthDataSpace #EUlaw #HealthClaims #NovelFoods</p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		<enclosure url="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4" length="12991488" type="video/mp4" />

			</item>
		<item>
		<title>Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Fri, 24 Jul 2026 15:14:06 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[aesthetic medicine]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[EU healthcare]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[health tech]]></category>
		<category><![CDATA[healthcare compliance]]></category>
		<category><![CDATA[healthcare innovation]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[Legal Compliance]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[MDR]]></category>
		<category><![CDATA[medical device advertising]]></category>
		<category><![CDATA[Medical Device Regulation]]></category>
		<category><![CDATA[Medical devices]]></category>
		<category><![CDATA[MedTech]]></category>
		<category><![CDATA[MedTech compliance]]></category>
		<category><![CDATA[pharma and healthcare]]></category>
		<category><![CDATA[Regulatory Affairs]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8836</guid>

					<description><![CDATA[<p>Publication date: July 24, 2026 Biostimulants in aesthetic medicine – current regulatory challenges for manufacturers, distributors and clinics The aesthetic medicine market is currently one of the fastest-growing healthcare segments in Europe. Particularly dynamic growth is observed in so-called tissue biostimulants, preparations used to stimulate the body&#8217;s natural regenerative processes. While traditional fillers dominated just [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/">Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 24, 2026</mark></strong></p>



<h2 class="wp-block-heading"><strong>Biostimulants in aesthetic medicine – current regulatory challenges for manufacturers, distributors and clinics</strong></h2>



<p id="ember53">The aesthetic medicine market is currently one of the fastest-growing healthcare segments in Europe. Particularly dynamic growth is observed in so-called tissue biostimulants, preparations used to stimulate the body&#8217;s natural regenerative processes. While traditional fillers dominated just a few years ago, today both manufacturers and physicians are increasingly turning to preparations containing poly-L-lactic acid (PLLA), calcium hydroxyapatite, polynucleotides, and collagen preparations, whose mechanism of action is based on the stimulation of tissue regeneration processes rather than solely on mechanical effects.</p>



<span id="more-8836"></span>



<p id="ember54">The growing popularity of these products, however, raises a number of legal questions. These concern not only their qualification as medical devices, but primarily the manner of communicating their properties and permissible forms of promotion. In practice, manufacturers, importers, distributors, and aesthetic medicine clinics increasingly face the dilemma of drawing the line between providing reliable product information and advertising, which is subject to stringent legal restrictions.</p>



<p id="ember55">This issue has become particularly important following the entry into force of the Act of April 7, 2022, on Medical Devices and the issuance of the Regulation of the Minister of Health on the Advertising of Medical Devices. Polish legislators have decided to introduce some of the most detailed regulations regarding the advertising of medical devices in Europe. These restrictions directly impact the activities of manufacturers, distributors, importers, healthcare providers, and marketing agencies serving the aesthetic medicine industry.</p>



<p id="ember56">At the same time, it&#8217;s important to remember that advertising medical devices does not operate in isolation from other legal regulations. Businesses must consider not only the provisions of Regulation (EU) 2017/745 on medical devices (MDR) and the Medical Devices Act, but also regulations on consumer protection, combating unfair market practices, combating unfair competition, personal data protection, and sometimes regulations governing the practice of medical professions and healthcare activities. Consequently, a single marketing campaign may be subject to simultaneous assessment under several different legal regimes.</p>



<p id="ember57">Particular difficulties arise with products used exclusively by individuals with appropriate professional qualifications. In practice, most biostimulants are administered via injection by a physician or other qualified medical professional. This raises the question of whether products intended exclusively for professional use can be advertised at all, and if not, how can businesses legally present information about their offerings on websites, social media, or at industry conferences.</p>



<p id="ember58">The purpose of this study is to present practical aspects of applying regulations regarding the advertising of medical devices, using tissue biostimulants as an example. Particular attention will be paid to the boundary between advertising and information, the obligations of manufacturers and distributors, the most common marketing errors, and compliance solutions that can reduce the risk of violating applicable regulations.</p>



<h2 class="wp-block-heading" id="ember59">Biostimulants – why do they raise so much legal controversy?</h2>



<p id="ember60">From a legal perspective, biostimulants constitute one of the most interesting categories of medical devices. Their specificity lies in the fact that, although formally subject to regulations specific to medical devices, their method of use, risk profile, and patient perception often resemble medicinal products more than traditional medical devices.</p>



<p id="ember61">In market practice, patients often fail to recognize the difference between a medicinal product and a biostimulant. Both types of products are administered in a doctor&#8217;s office, require medical qualifications, involve intervention in the body, and may cause adverse reactions. Therefore, for the average consumer, the difference between a medicinal product and a medical device remains almost invisible.</p>



<p id="ember62">From the perspective of EU law, however, what matters most is not the method of administration or the site of use, but the mechanism by which the principal intended action is achieved. The MDR is based on a fundamental distinction between medicinal products and medical devices. If the principal action is achieved by pharmacological, immunological, or metabolic means, the product will generally be classified as a medicinal product. However, if the mechanism of action is based on other properties &#8211; for example, physical or mechanical &#8211; the product may be classified as a medical device, even if its use leads to long-term biological effects.</p>



<p id="ember63">This very boundary has been the subject of numerous interpretational disputes for years. In the case of biostimulants, the preparation does not replace natural processes occurring in the body nor does it produce a therapeutic effect through a pharmacological mechanism. Its purpose is to create conditions enabling the activation of natural regenerative processes, such as stimulating fibroblasts to produce collagen or rebuilding the extracellular matrix. It is this mechanism that causes most currently available biostimulants to be classified as medical devices.</p>



<p id="ember64">This does not mean, however, that all products marketed as &#8220;biostimulants&#8221; automatically fall into the same regulatory category. Legal classification is determined by a case-by-case analysis of the specific product, its intended use, and the mechanism of action specified by the manufacturer. In practice, there are also products that, despite similar aesthetic applications, may be subject to different legal regimes, including regulations concerning medicinal products, cosmetics, and medical devices.</p>



<p id="ember65">This is fundamental for subsequent marketing communications. Already at the product qualification stage, the manufacturer should consider the target audience, the information that can be conveyed to recipients, and the advertising restrictions that will apply. Mistakes made at this stage often result in the need to redesign the entire marketing strategy after the product has been launched.</p>



<h2 class="wp-block-heading" id="ember66">Can biostimulants be advertised? Limitations under the Medical Devices Act and the MDR Regulation</h2>



<p id="ember67">One of the most frequently asked questions by manufacturers, importers, and healthcare providers is whether biostimulants can be advertised to a broad audience. The answer to this question is ambiguous and requires consideration of both the provisions of the EU MDR Regulation, the Polish Medical Devices Act, and implementing regulations governing advertising.</p>



<p id="ember68">In practice, a certain pattern can be observed. Many entrepreneurs equate the fact that a product has been legally introduced to the market with the ability to freely promote it. However, this assumption is incorrect. Approval of a medical device for marketing does not automatically mean that the manufacturer or distributor can use any marketing tools. On the contrary, the more specialized the product and the greater the risk associated with its use, the greater the restrictions on its communication.</p>



<p id="ember69">In the case of biostimulants, it is particularly important that the vast majority of these products are intended for use only by individuals with appropriate professional qualifications. Treatments using them require medical qualification, maintaining appropriate aseptic conditions, and injections performed in accordance with medical knowledge. Therefore, the recipient of the product is not the patient, but a medical professional who then uses the product while providing healthcare services or aesthetic medicine treatments.</p>



<p id="ember70">This circumstance is of fundamental importance from the perspective of advertising law.</p>



<h2 class="wp-block-heading" id="ember71">Advertising of medical devices is not advertising of consumer products.</h2>



<p id="ember72">The Medical Devices Act adopts different assumptions than the regulations governing the advertising of ordinary consumer goods. The legislator&#8217;s goal was not to create freedom in marketing activities, but to ensure that decisions regarding the use of medical devices are made primarily based on medical knowledge, not advertising messages.</p>



<p id="ember73">For this reason, the legislator decided to introduce numerous restrictions on both the content of advertising and its target audience. In practice, this means that, already at the design stage of a marketing campaign, entrepreneurs should answer three fundamental questions:</p>



<ul class="wp-block-list">
<li>who is the actual user of the product,</li>



<li>to whom the message is addressed,</li>



<li>whether the information provided is of a promotional nature or purely informational.</li>
</ul>



<p id="ember75">Only a combined analysis of these elements allows us to assess the compliance of the planned communication with applicable regulations.</p>



<h2 class="wp-block-heading" id="ember76">The intended use of the product is crucial.</h2>



<p id="ember77">In practice, there&#8217;s a common misconception that advertising opportunities are determined solely by how a product is sold. This isn&#8217;t the correct approach.</p>



<p id="ember78">The manufacturer&#8217;s intended use of the product and the user group specified in the technical documentation and instructions for use are of much greater importance. If the manufacturer has specified that the product should only be used by professionals, this also influences the assessment of the admissibility of directing marketing messages to individuals without medical qualifications.</p>



<p id="ember79">This is precisely the situation with most biostimulants. These products are intended for procedures requiring appropriate professional training, knowledge of anatomy, aseptic techniques, and the ability to recognize contraindications. From a regulatory perspective, it would be difficult to justify extensive advertising campaigns aimed at the general public when the product itself cannot be used independently by the average consumer.</p>



<p id="ember80">This doesn&#8217;t mean, however, that businesses cannot provide any information regarding such products. On the contrary, the law permits the provision of information about medical devices, but the line between information and advertising requires individual assessment.</p>



<h2 class="wp-block-heading" id="ember81">Advertising and information – why is the distinction so important?</h2>



<p id="ember82">In practice, the vast majority of disputes concerning medical device advertising do not focus on obvious promotional campaigns. Much more often, the problem arises with materials that businesses define as &#8220;informational,&#8221; while from the perspective of regulatory authorities, they may be considered advertising.</p>



<p id="ember83">Importantly, neither the MDR nor the Medical Devices Act provide a legal definition of medical device advertising. However, the lack of a statutory definition does not imply any freedom of interpretation. Case law and doctrine assume that the nature of a message is primarily determined by its actual purpose, not the name given to it by the trader.</p>



<p id="ember84">If the primary purpose of the message is to increase interest in the product, build a positive image of the product or encourage its purchase or use, there is a high probability that the message will be classified as advertising, regardless of whether it contains a direct call to purchase.</p>



<p id="ember85">In practice, this means that even seemingly neutral materials may be considered advertising if they are prepared in a way that highlights only the advantages of the product, ignores its limitations or uses characteristic marketing techniques.</p>



<h2 class="wp-block-heading" id="ember86">Is the manufacturer&#8217;s website itself an advertisement?</h2>



<p id="ember87">This is one of the most frequently asked questions in the practice of law firms advising manufacturers of medical devices.</p>



<p id="ember88">There is no single universal answer to this question.</p>



<p id="ember89">The mere presence of product information on a website does not constitute advertising. A website can function as a product catalog, a database of technical documentation, or a platform for communicating with medical professionals. However, if the product&#8217;s presentation goes beyond providing objective information and begins to utilize typical marketing mechanisms, the risk of such communication being classified as advertising significantly increases.</p>



<p id="ember90">For example, posting instructions for use, declarations of conformity, technical data, or information on how to use a product on a website will generally be informative. However, a situation in which the same website includes slogans such as &#8220;revolutionary rejuvenation method,&#8221; &#8220;the most effective biostimulator available on the market,&#8221; &#8220;instant lifting effect,&#8221; or &#8220;spectacular results guaranteed&#8221; should be assessed differently. In such cases, the message goes beyond neutral information and begins to serve a promotional purpose.</p>



<p id="ember91">Therefore, designing websites for medical device manufacturers requires close collaboration between marketing departments and legal and regulatory affairs departments . In practice, even seemingly minor changes in product presentation can result in a different legal classification for the entire message.</p>



<h2 class="wp-block-heading" id="ember92">The boundary between advertising and information – practical problems of producers and aesthetic medicine clinics</h2>



<p id="ember93">While the distinction between advertising and information seems intuitive, in practice it is one of the most problematic issues related to the functioning of the medical device market. This stems primarily from the fact that contemporary marketing communication rarely takes the form of classic television or print advertising. Businesses much more frequently utilize websites, social media, newsletters, podcasts, webinars , expert blogs, and educational materials. Each of these forms can—depending on how it is prepared—be considered both neutral information and advertising.</p>



<p id="ember94">In practice, there is no single element that automatically determines the classification of a given message. Supervisory authorities and courts analyze all the circumstances, taking into account the content of the message, its form, presentation, audience, and the actual purpose of the publication. This means that even a message containing only truthful information may be considered advertising if its primary purpose is to encourage the purchase or use of a product.</p>



<p id="ember95">For this reason, businesses should move away from the simple question: &#8220;Are we allowed to publish this information?&#8221; and instead ask themselves: &#8220;How will the average recipient perceive this message?&#8221; It is the recipient&#8217;s perspective, not the business&#8217;s intention, that will in many cases determine the legality of the message.</p>



<h2 class="wp-block-heading" id="ember96">Website – an entrepreneur&#8217;s business card or an advertising tool?</h2>



<p id="ember97">The first place where doubts arise is almost always the manufacturer&#8217;s, distributor&#8217;s, or clinic&#8217;s website. For many businesses, it is their primary channel of communication with the market, yet it is also one of the most frequently scrutinized elements during inspections conducted by regulatory authorities.</p>



<p id="ember98">The mere presence of information about a medical device on a website is not prohibited. Businesses have the right to present information about the products offered, their properties, methods of use, technical documentation, and instructions for use. However, problems arise when the presentation method goes beyond providing objective information.</p>



<p id="ember99">A good example is comparing two descriptions of the same product.</p>



<p id="ember100">The first one could be as follows:</p>



<p id="ember101">&#8220;A preparation intended for the reconstruction of tissue volume in accordance with the instructions for use. The product is intended for use by qualified medical professionals.&#8221;</p>



<p id="ember102">This description is for informational purposes only. It is limited to presenting the product&#8217;s intended use and user group.</p>



<p id="ember103">The following message should be assessed differently:</p>



<p id="ember104">&#8220;The most innovative biostimulator on the market. It instantly rejuvenates the skin and provides a spectacular lifting effect after just one treatment.&#8221;</p>



<p id="ember105">Although both messages refer to the same product, the second employs typical marketing tactics. It uses evaluative terms (&#8220;the most innovative,&#8221; &#8220;spectacular effect&#8221;), promises of effectiveness, and suggests a competitive advantage. This type of message is difficult to consider as neutral technical information.</p>



<p id="ember106">In practice, this means that entrepreneurs should analyze not only the content of the information, but also the way it is expressed. Often, it is individual marketing terms that determine the overall nature of the message.</p>



<h2 class="wp-block-heading" id="ember107">Newsletters and mailings to customers</h2>



<p id="ember108">Another tool increasingly used by manufacturers and distributors is newsletters and emails directed to customers. Again, not every message can be considered advertising.</p>



<p id="ember109">If a newsletter contains information about changes in regulations, new regulatory requirements, announcements from supervisory authorities, or changes to product instructions, it will generally serve an informative purpose. However, messages whose primary purpose is to increase sales of a specific product should be assessed differently.</p>



<p id="ember110">For example, a message titled &#8220;Changes to MDR requirements for technical documentation&#8221; would be educational in nature. An email with the slogan &#8220;Discover the most effective biostimulant available on the market – order today&#8221; would undoubtedly serve an advertising function.</p>



<p id="ember111">This does not, of course, prohibit commercial communication. However, entrepreneurs should remember that such communication is subject to all restrictions applicable to advertising medical devices.</p>



<h2 class="wp-block-heading" id="ember112">Webinars and training – education or product promotion?</h2>



<p id="ember113">The significant increase in the popularity of webinars organized by medical device manufacturers has also led to this form of communication starting to attract the attention of supervisory authorities.</p>



<p id="ember114">Organizing training for doctors and other medical professionals is nothing unusual. On the contrary, in many cases, proper user training is an essential element in ensuring the safe use of a device.</p>



<p id="ember115">The problem arises, however, when a webinar described as a &#8220;scientific training&#8221; actually focuses almost exclusively on promoting one product, highlighting its advantages while omitting limitations, contraindications, and alternative methods of treatment.</p>



<p id="ember116">In practice, it is worth adopting the principle that the more educational the material is, the greater the emphasis should be on presenting objective medical knowledge, and not only information beneficial to the manufacturer.</p>



<h2 class="wp-block-heading" id="ember117">Scientific conferences</h2>



<p id="ember118">Similar problems apply to industry conferences. Sponsorship of scientific events by medical device manufacturers is common practice and raises no objections in itself. However, risks arise when the scientific component is subordinated to marketing objectives.</p>



<p id="ember119">In practice, particular caution should be exercised when presenting research results for a specific product. Results should be presented honestly, taking into account methodological limitations and the full clinical context. Selectively presenting only favorable data may be viewed as misleading.</p>



<p id="ember120"><strong>LinkedIn – professional communication can also be advertising</strong></p>



<p id="ember121">Many content creators assume that since LinkedIn is primarily a professional platform, the content published there is strictly business-related. However, this assumption is far-fetched.</p>



<p id="ember122">If a LinkedIn entry is limited to information about participation in a conference, obtaining a certificate, a scientific publication or organizational changes in the company, it is generally difficult to attribute an advertising nature to it.</p>



<p id="ember123">However, if a publication contains incentives to use a specific product, comparisons with competitive products, promises of specific clinical effects or highlights the advantages of a product in order to increase sales, it may be considered advertising, regardless of the fact that it was published on a professional website.</p>



<p id="ember124">LinkedIn is increasingly being used as a marketing platform for the healthcare market. Therefore, communications conducted via this platform should also be subject to the company&#8217;s internal compliance procedures.</p>



<p id="ember125"><strong>Social media – the biggest challenge for the biostimulant market</strong></p>



<p id="ember126">Social media has completely transformed the way patients make decisions. Just a dozen or so years ago, the primary source of information was a doctor&#8217;s consultation and manufacturer-provided materials. Today, many patients primarily seek information on Instagram, TikTok, Facebook, and YouTube, guided by the opinions of influencers , physicians with educational profiles, and other users&#8217; testimonials.</p>



<p id="ember127">For entrepreneurs, this represents a huge marketing opportunity, but also significant regulatory risk. Traditional regulations regarding medical device advertising were designed with press, radio, and television advertising in mind. Modern online communication is much more dynamic and often combines elements of education, personal branding, and product promotion. As a result, assessing the legality of a specific message requires a case-by-case analysis of its actual purpose and context.</p>



<h2 class="wp-block-heading" id="ember128">Instagram – where does education end and advertising begin?</h2>



<p id="ember129">Instagram remains the most important communication channel used by aesthetic medicine clinics and physicians performing biostimulant treatments. This platform relies primarily on visual communication, which inherently has a stronger impact on audiences than traditional product descriptions.</p>



<p id="ember130">From a legal perspective, however, it cannot be assumed that every post about a procedure constitutes advertising. Physicians have the right to conduct educational activities, explain the mechanisms of individual procedures, discuss indications and contraindications, and comment on scientific publications. Such activities contribute to increasing patient awareness and should not, in and of themselves, be equated with advertising.</p>



<p id="ember131">The line is crossed when communication begins to focus on promoting a specific medical device or building its commercial appeal. This applies particularly to publications containing marketing slogans, incentives for procedures, information about price promotions, comparisons with competing products, or emphasizing the exceptional effectiveness of a specific product without providing the full medical context.</p>



<p id="ember132">In practice, it is worth adopting the rule that the more a post resembles advertising material prepared by a marketing agency, the greater the risk of it being classified as an advertisement for a medical device.</p>



<h2 class="wp-block-heading" id="ember133">TikTok – short form does not exempt from responsibility</h2>



<p id="ember134">Just a few years ago, few medical device manufacturers considered TikTok a business communication tool. Today, the situation is completely different. More and more clinics are publishing short videos demonstrating treatment procedures, patient reactions, and the aesthetic effects achieved after using specific products.</p>



<p id="ember135">The specific nature of this platform, however, means that the message is necessarily simplified. A video lasting several dozen seconds rarely allows for the presentation of contraindications, possible side effects, or limitations of the product&#8217;s use. As a result, there is an increased risk of creating a one-sided image of the product, highlighting only its benefits.</p>



<p id="ember136">From a compliance perspective , businesses should therefore exercise particular caution when preparing materials published on platforms based on short audiovisual forms. Merely shortening the message does not exempt them from ensuring its compliance with regulations on advertising medical devices.</p>



<h2 class="wp-block-heading" id="ember137">Influencer Marketing – New Regulatory Risk</h2>



<p id="ember138">influencers remains one of the most dynamically developing areas of marketing. This phenomenon has also impacted the aesthetic medicine market. Increasingly, individuals with significant social media followings are publishing treatment reports, presenting their recovery processes, and describing their own experiences using specific products.</p>



<p id="ember139">From a legal perspective, such collaboration requires special caution. Even if the influencer doesn&#8217;t mention a specific product, the way the treatment is presented can lead to increased interest in a specific technology or manufacturer. If the publication is created as part of a commercial collaboration, additional obligations arise under regulations regarding labeling advertising content and consumer protection.</p>



<p id="ember140">In practice, the producer should remember that responsibility for the legality of the message is not always limited solely to the influencer. Depending on the cooperation model, the entrepreneur initiating the campaign may also be responsible for the manner in which marketing communications are conducted.</p>



<p id="ember141"><strong>Doctor as a product ambassador</strong></p>



<p id="ember142">The use of physicians&#8217; authority to promote medical products remains a particularly sensitive issue. Public trust in medical professionals means their statements have a much greater impact than traditional advertising messages.</p>



<p id="ember143">This doesn&#8217;t mean, however, that doctors cannot publicly comment on the technologies they use. On the contrary, sharing medical knowledge, clinical experience, and research results is a crucial element in the development of medical science and practice. The problem arises only when a doctor&#8217;s statement ceases to be expert-based and begins to serve a marketing function.</p>



<p id="ember144">The risk increases especially when a physician appears in manufacturer-produced materials, uses promotional language, or explicitly encourages consumers to choose a specific product. In such cases, the regulatory authority may determine that the use of the medical profession&#8217;s authority serves to increase the product&#8217;s commercial appeal, which requires assessment from the perspective of regulations governing the advertising of medical devices.</p>



<h2 class="wp-block-heading" id="ember145">Before &#8211; after photos – an effective marketing tool or a source of risk?</h2>



<p id="ember146">One of the most distinctive elements of communication in aesthetic medicine is photographs depicting the patient&#8217;s appearance before and after the procedure. From a marketing perspective, this is an extremely effective tool for influencing potential clients. However, from a legal perspective, its use raises a number of concerns.</p>



<p id="ember147">Firstly, such materials often lead the recipient to believe that the treatment will provide a guaranteed result. However, the results of medical procedures depend on numerous individual factors, such as the patient&#8217;s health, age, biological predispositions, and adherence to post-treatment recommendations . Presenting single, spectacular results can lead to unrealistic expectations.</p>



<p id="ember148">Secondly, publishing patient photos requires compliance with regulations on personal data protection and the protection of personal rights. Consent to perform a procedure does not constitute consent to the dissemination of the image. The provider should obtain separate, informed, and voluntary consent covering the publication of photographs in specific communication channels.</p>



<p id="ember149">Third, it&#8217;s important to remember that even properly obtained patient consent doesn&#8217;t eliminate the risk of a publication being considered an advertisement for a medical device. If a photo is used to promote a specific product or increase interest in a specific procedure, the entire message should be assessed in light of advertising regulations.</p>



<p id="ember150">In practice, this means that the use of &#8221; before &#8211; after &#8221; photography requires simultaneous analysis from the perspective of medical device law, personal data protection, civil law, and consumer protection regulations. Failure to consider even one of these aspects can lead to significant legal risk.</p>



<h2 class="wp-block-heading" id="ember151">Misleading advertising – why can a truthful message also violate the law?</h2>



<p id="ember152">One of the most common mistakes made by businesses operating in the medical device market is the belief that because all information contained in an advertisement is truthful, the message is automatically legal. However, this assumption is far-fetched and is not supported by either the EU MDR or national regulations regarding medical device advertising.</p>



<p id="ember153">Assessing the legality of advertising is not limited to verifying the veracity of individual claims. Equally important are the manner in which they are presented, the context of the overall message, and the potential impact on the recipient&#8217;s decisions. Advertising can be misleading not only by providing false information, but also by selectively presenting facts, omitting important limitations, or emphasizing only the positive aspects of a product&#8217;s use.</p>



<p id="ember154">This is why Article 7 of the MDR should be considered one of the key regulations governing the marketing communications of medical device manufacturers. This provision prohibits the use of texts, names, trademarks, images, symbols, or other markings that could mislead the user or patient regarding the intended purpose, safety, or performance of the device. This prohibition applies not only to labels and instructions for use but also to advertising materials and other forms of market communication.</p>



<p id="ember155">In practice, this means that an entrepreneur should analyze each message not only in terms of compliance with the product&#8217;s technical documentation, but also from the perspective of how the average recipient might interpret the information presented.</p>



<p id="ember156"><strong>Not only falsehood, but also silence</strong></p>



<p id="ember157">One of the most frequently underestimated aspects of advertising is the responsibility for omitting information that is important to the recipient. Businesses typically focus on avoiding false claims, much less on analyzing the consequences of omitting specific information.</p>



<p id="ember158">Imagine an advertisement for a biostimulator in which the manufacturer presents excellent aesthetic results achieved after the treatment. All photographs are authentic, and the description of the effects reflects the actual experiences of selected patients. At the same time, the advertisement contains no information about the need for medical qualification, possible contraindications, the risk of side effects, or the body&#8217;s varied response to treatment.</p>



<p id="ember159">Formally, none of the claims presented are false. Nevertheless, the recipient may be misled into thinking that achieving the presented effect is typical, predictable, and practically guaranteed. Consequently, the message may be considered misleading because it creates unrealistic expectations regarding the product&#8217;s performance.</p>



<p id="ember160">A similar risk arises when using terms such as &#8220;safe,&#8221; &#8220;non-invasive,&#8221; &#8220;natural,&#8221; or &#8220;side-effect-free.&#8221; Even if a product has a high safety profile, using such phrases can imply an absence of risk, which is difficult to reconcile with clinical reality.</p>



<h2 class="wp-block-heading" id="ember161">Can we use the terms “best”, “most effective” or “revolutionary”?</h2>



<p id="ember162">Marketing language often relies on the use of evaluative terms. Advertisements feature phrases such as &#8220;market leader,&#8221; &#8220;the most innovative product,&#8221; &#8220;the best rejuvenation technology,&#8221; or &#8220;a breakthrough in aesthetic medicine.&#8221; In the consumer goods sector, this type of communication is common. However, when it comes to medical devices, much greater caution is required.</p>



<p id="ember163">First, an entrepreneur should have objective evidence to support any comparative or evaluative claim. Second, even the existence of scientific research does not always justify the use of terms suggesting absolute superiority over all competing solutions. In medical practice, the effectiveness of therapy depends on many factors, including the patient&#8217;s qualifications, the physician&#8217;s experience, and individual biological conditions.</p>



<p id="ember164">From a compliance perspective, a much safer solution is to use a description based on clinical trial results and technical parameters of the product, instead of using general marketing slogans.</p>



<p id="ember165"><strong>Practice of supervisory authorities – the growing importance of digital communication</strong></p>



<p id="ember166">Recent years have seen a significant increase in supervisory authorities&#8217; interest in online communications. While previously, oversight activities focused primarily on traditional advertising materials, they now also analyze websites, social media profiles, newsletters, videos published on streaming platforms , and collaborations with influencers.</p>



<p id="ember167">This trend is consistent with a broader trend observed at the EU level, where increasing emphasis is being placed on countering manipulative marketing practices and ensuring a high level of protection for consumers using healthcare services. Consequently, businesses should assume that online communications are subject to the same scrutiny as traditional forms of advertising.</p>



<h2 class="wp-block-heading" id="ember168">The Polish Office of Competition and Consumer Protection and consumer protection – the second pillar of responsibility</h2>



<p id="ember169">Although the primary legislation regulating the advertising of medical devices remains the Medical Devices Act, businesses cannot limit their analysis solely to this legal regime. Consumer protection regulations also apply, in particular the Act on Combating Unfair Market Practices and the Act on Competition and Consumer Protection.</p>



<p id="ember170">From the perspective of the President of the Office of Competition and Consumer Protection (UOKiK), the impact of a message on the average consumer is of particular importance. If a communication exploits emotions, raises unjustified expectations, or suggests characteristics that the recipient is unable to independently verify, it may be considered a practice that violates the collective interests of consumers.</p>



<p id="ember171">In practice, this means that a single marketing campaign may be assessed simultaneously by different authorities under different legal frameworks. Manufacturers should therefore design their marketing activities to ensure compliance not only with medical device regulations but also with consumer protection and fair competition regulations.</p>



<p id="ember172"><strong>Compliance instead of reaction after inspection</strong></p>



<p id="ember173">Experience in recent years shows that a significant number of violations are not the result of deliberate actions by businesses, but rather a lack of appropriate internal procedures. Marketing materials are often prepared by external advertising agencies that are intimately familiar with the mechanisms of selling consumer products but lack experience in the regulated sector.</p>



<p id="ember174">compliance systems that encompass the entire marketing communications process is becoming increasingly important . Every piece of content &#8211; whether it&#8217;s an Instagram post, a product brochure, a webinar , or a YouTube video &#8211; should be reviewed not only by the marketing department but also by those responsible for regulatory and legal matters.</p>



<p id="ember175">This approach allows for the identification of risks before the material is published, reducing the likelihood of initiating administrative proceedings, disputes with supervisory authorities and negative image consequences.</p>



<h2 class="wp-block-heading" id="ember176">The most common mistakes of manufacturers, importers, distributors and clinics – what to avoid in practice?</h2>



<p id="ember177">Recent experience shows that most violations of regulations regarding medical device advertising do not result from deliberate disregard for applicable regulations. Quite the opposite – entrepreneurs operating in the aesthetic medicine market typically strive to conduct their business in compliance with the law, but they encounter difficulties resulting from ambiguous regulations and the dynamic development of modern communication channels. Marketing of medical products is increasingly conducted via social media, educational platforms, and industry events, whereas existing regulations were primarily designed with traditional forms of advertising in mind.</p>



<p id="ember178">In practice, however, there are several recurring mistakes that occur regardless of the size of the company and which should be taken into account when designing a marketing strategy.</p>



<p id="ember179"><strong>Mistake No. 1 – Equating commercial information with neutral information</strong></p>



<p id="ember180">One of the most common misconceptions is that material doesn&#8217;t constitute advertising solely because a business owner has designated it as &#8220;information.&#8221; This approach is unsupported by applicable law.</p>



<p id="ember181">The nature of a message is assessed based on its actual function, not the name given by the author. If the material highlights the benefits of a specific product, builds its market appeal, or is intended to encourage the recipient to choose a specific product, there is a high probability that it will be classified as an advertisement, even if it does not contain a classic call to purchase.</p>



<p id="ember182">An example would be an article published on the manufacturer&#8217;s website titled &#8220;Modern Skin Regeneration Possibilities.&#8221; If the majority of the text is devoted to a single product, highlights its advantages over the competition, and leads to a contact form allowing purchase of the product or registration for training, it&#8217;s difficult to consider such material solely educational.</p>



<p id="ember183">In practice, entrepreneurs should remember that supervisory authorities analyze not only the content of the publication, but also its location, method of presentation and connection with the entrepreneur&#8217;s business activity.</p>



<p id="ember184"><strong>Mistake #2 – Copying Cosmetic Product Marketing</strong></p>



<p id="ember185">The aesthetic medicine market is developing in parallel with the cosmetics market, resulting in many marketing activities being mutually inspired. However, from a regulatory perspective, this approach can lead to serious problems.</p>



<p id="ember186">Cosmetics marketing relies primarily on building emotions, visual appeal, and creating a specific lifestyle. Meanwhile, communication regarding medical devices is subject to much more stringent requirements. Using identical marketing techniques for products covered by the MDR may lead to violations of advertising regulations, especially if the message ignores the limitations imposed by the product&#8217;s intended use or its method of use.</p>



<p id="ember187">In practice, this means that the marketing department of a medical device manufacturer should not automatically use solutions used in cosmetic campaigns, even if they seem effective from a business point of view.</p>



<p id="ember188"><strong>Mistake No. 3 – overexposing the effects of the treatment</strong></p>



<p id="ember189">Marketing materials for biostimulants often focus almost exclusively on aesthetic effects. Images depicting wrinkle smoothing, facial contour improvement, or increased skin firmness undoubtedly attract audiences and enhance the message&#8217;s appeal.</p>



<p id="ember190">The problem, however, is that the results of aesthetic medicine treatments are individual. They depend on the patient&#8217;s age, health, skin condition, previous medical procedures, lifestyle, and the experience of the practitioner. Presenting individual, exceptionally positive results without proper context can lead to unrealistic expectations on the part of potential patients.</p>



<p id="ember191">From a compliance perspective , it is much safer to present information about the mechanism of action of the product and its intended use than to focus all communication on spectacular visual effects.</p>



<p id="ember192"><strong>Mistake No. 4 – Ignoring contraindications and limitations of use</strong></p>



<p id="ember193">Another common mistake is presenting a product solely through the lens of its benefits. Marketing materials often emphasize the product&#8217;s effectiveness, innovation, and safety, while failing to mention situations in which its use may be inadvisable.</p>



<p id="ember194">Meanwhile, reliable communication regarding medical devices should also include information about contraindications, limitations of use, and the need for medical qualification. This doesn&#8217;t mean, of course, that every advertisement must include full instructions for use, but omitting all information regarding potential risks could lead to accusations of misleading consumers.</p>



<p id="ember195"><strong>Mistake #5 – Lack of cooperation between marketing and legal departments</strong></p>



<p id="ember196">In many companies, marketing materials are prepared by external creative agencies or marketing departments that lack specialized knowledge of medical device regulations. Only then does the completed material reach the legal department, often just prior to publication.</p>



<p id="ember197">affairs specialists and lawyers at the marketing campaign design stage. This avoids the need for later material withdrawal or costly modification.</p>



<p id="ember198"><strong>Mistake #6 – Lack of social media procedures</strong></p>



<p id="ember199">Many companies have extensive procedures for approving product catalogs and printed materials, yet they don&#8217;t regulate the rules for publishing content on social media. Yet, it&#8217;s short posts on Instagram, Facebook, and LinkedIn that are currently published most frequently and have the greatest impact on a company&#8217;s image.</p>



<p id="ember200">The lack of internal guidelines leads individual employees to publish content at their own discretion, often unaware of the legal consequences of using specific phrases or photographs. In practice, it&#8217;s worth developing separate policies for online communication, covering topics such as product presentation, use of photographic materials, publishing coverage of industry events, and collaborating with physicians and influencers.</p>



<p id="ember201"><strong>Compliance practices – how to organize legal marketing communications?</strong></p>



<p id="ember202">Compliance system shouldn&#8217;t be limited to merely responding to emerging issues. Its primary goal is to prevent violations by establishing transparent rules for preparing and approving marketing materials.</p>



<p id="ember203">In practice, a growing number of medical device manufacturers are implementing multi-stage approval procedures involving marketing departments, regulatory affairs specialists, quality control departments, and lawyers. This model allows for the assessment of a material not only in terms of its marketing appeal but also its compliance with the product&#8217;s technical documentation, instructions for use, and applicable regulations.</p>



<p id="ember204">Maintaining documentation of the approval process is also particularly important. In the event of an audit, the company should be able to demonstrate that the materials were prepared in accordance with internal procedures and reviewed by appropriately qualified individuals. Archiving subsequent versions of materials, legal opinions, and publication decisions can be of significant evidentiary value.</p>



<p id="ember205">In practice, a well-functioning compliance system shouldn&#8217;t be perceived as an obstacle to marketing activities. On the contrary, properly designed procedures enable legally secure communication, reducing the risk of administrative sanctions and disputes with supervisory authorities, while building trust with customers and business partners.</p>



<p id="ember206"><strong>European perspective – why will the importance of compliance systematically grow?</strong></p>



<p id="ember207">Polish regulations on medical device advertising are currently among the most detailed in the European Union. However, this does not mean that businesses operating in the domestic market can limit themselves solely to knowledge of the provisions of the Medical Devices Act and the Regulation of the Minister of Health. The functioning of the medical devices market is increasingly determined by the practice of applying the MDR, the positions of EU bodies, and the actions of national regulatory authorities in individual member states.</p>



<p id="ember208">The MDR does not contain comprehensive regulations on the advertising of medical devices. It focuses primarily on product safety, manufacturers&#8217; obligations, conformity assessment, and the rules for placing devices on the market. At the same time, Article 7 of the MDR establishes the general principle that all communication about a device – regardless of its form – must not mislead users or patients about the product&#8217;s intended purpose, properties, safety, or efficacy.</p>



<p id="ember209">In practice, this provision serves a much broader purpose than the classic ban on misleading advertising. It constitutes a specific interpretative principle that should be considered when assessing every form of communication conducted by a manufacturer or distributor. Increasingly, supervisory authorities are moving away from formalistic analysis of individual advertising slogans and focusing on the overall perception of the message by the average user.</p>



<p id="ember210">At the same time, the activities of <strong>Medical Device Coordination Group (MDCG) </strong>highlights the growing importance of transparent information provided to users of medical devices. Although MDCG documents are not legally binding, in practice they guide the interpretation of MDR provisions by national authorities and notified bodies. Increasing emphasis is being placed on ensuring consistency between a device&#8217;s technical documentation, instructions for use, and market communications.</p>



<p id="ember211">It can be predicted that in the coming years, marketing control will encompass not only traditional advertising but also recommendation algorithms of online platforms, message personalization, the use of artificial intelligence in marketing, and automated advertising profiles. The development of new technologies is blurring the lines between information, advertising, and educational content.</p>



<p id="ember212">For manufacturers, this means moving away from a one-time approach to assessing marketing materials. Implementing ongoing compliance procedures that enable ongoing assessment of communications&#8217; compliance with rapidly evolving regulatory requirements will be much more effective.</p>



<h2 class="wp-block-heading" id="ember213">Practical checklist compliance before publishing marketing materials</h2>



<p id="ember214">In practice, most violations can be avoided by implementing simple verification procedures. Before publishing material regarding a medical device, it&#8217;s important to answer the following questions:</p>



<p id="ember215"><strong>First</strong>, is the product intended for use by laypeople or exclusively by professionals? The answer to this question determines the acceptable scope of communication and the target audience.</p>



<p id="ember216"><strong>Secondly</strong>, is the planned material truly informative, or is its primary purpose to increase interest in the product? When in doubt, it&#8217;s worth adopting a more cautious approach and evaluating the message according to advertising principles.</p>



<p id="ember217"><strong>Third</strong>, are all claims regarding product properties supported by technical documentation, instructions for use, and conformity assessment results? Marketing departments should not independently make new claims regarding product effectiveness or safety.</p>



<p id="ember218"><strong>Fourthly</strong>, does the material use evaluative terms such as &#8220;best&#8221;, &#8220;most effective&#8221;, &#8220;revolutionary&#8221; or &#8220;guaranteed effect&#8221;, the validity of which could be questioned by the supervisory authority?</p>



<p id="ember219"><strong>Fifth</strong>, does the message include product use restrictions, the need for medical qualification, and other information relevant to user safety?</p>



<p id="ember220"><strong>Sixth</strong>, does the publication contain photographs or recordings of patients? If so, it is necessary to verify not only compliance with regulations on advertising medical devices, but also the basis for processing personal data, the scope of consent granted, and the protection of personal rights.</p>



<p id="ember221"><strong>Seventh</strong>, was the material reviewed by those responsible for regulatory and legal matters? In practice, even minor linguistic changes can significantly alter the legal assessment of the entire message.</p>



<p id="ember222"><strong>Eighth</strong>, does the entrepreneur have documentation confirming the material approval process? In the event of an audit, the ability to demonstrate organizational diligence can be crucial to assessing the entrepreneur&#8217;s actions.</p>



<h2 class="wp-block-heading" id="ember223">Summary</h2>



<p id="ember224">The development of the biostimulator market is one of the most dynamic areas in contemporary aesthetic medicine. These products respond to growing patient expectations for natural tissue regeneration methods, while simultaneously posing entirely new regulatory challenges for manufacturers, importers, distributors, and healthcare providers.</p>



<p id="ember225">Contrary to popular belief, the biggest problem today isn&#8217;t the mere ability to advertise. The key challenge remains the ability to communicate effectively, while simultaneously providing accurate product information and complying with stringent legal requirements. The line between information and advertising is becoming increasingly blurred, especially in the digital environment, where communication occurs via social media, educational platforms, and artificial intelligence tools.</p>



<p id="ember226">From the perspective of entrepreneurs, this means a shift in thinking about medical device marketing. Instead of treating compliance as a final stage of reviewing advertising materials, it&#8217;s worth viewing them as an integral element of the process of designing market communication. Early involvement of legal, regulatory, and quality specialists not only reduces the risk of administrative sanctions but also builds brand credibility and audience trust.</p>



<p id="ember227">It can be expected that the requirements for communication transparency will systematically increase in the coming years. The development of artificial intelligence, data-driven marketing, and message personalization will force supervisory authorities to increasingly scrutinize not only the content of advertisements but also their distribution and impact on audience decisions. In this environment, competitive advantage will be achieved not by those businesses that conduct the most aggressive marketing communications, but by those that manage to combine innovation with regulatory responsibility.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/">Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/biostimulants-under-the-microscope-of-the-law-where-does-information-end-and-prohibited-advertising-of-medical-devices-begin/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>A Major Milestone for KG Legal&#8217;s Data, AI &#038; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 19:32:01 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[AI Compliance]]></category>
		<category><![CDATA[AI Regulation]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Corporate Counsel]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Cross Border Legal Services]]></category>
		<category><![CDATA[Cyber Compliance]]></category>
		<category><![CDATA[Cyber Law]]></category>
		<category><![CDATA[Data Governance]]></category>
		<category><![CDATA[Data Privacy]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[DataGuidance]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Digital Economy]]></category>
		<category><![CDATA[Digital Law]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Emerging Technologies]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Law]]></category>
		<category><![CDATA[Foreign Investors]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[GDPR Compliance]]></category>
		<category><![CDATA[GDPR Poland]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[Global Law]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Healthcare Regulation]]></category>
		<category><![CDATA[In House Counsel]]></category>
		<category><![CDATA[International Law Firm]]></category>
		<category><![CDATA[International Legal Services]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm Poland]]></category>
		<category><![CDATA[Legal Innovation]]></category>
		<category><![CDATA[Legal Tech]]></category>
		<category><![CDATA[Legal Thought Leadership]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[NIS2]]></category>
		<category><![CDATA[OneTrust]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Polish Law Firm]]></category>
		<category><![CDATA[Privacy Law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Technology Law]]></category>
		<category><![CDATA[Technology Transactions]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8822</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 We are delighted to share an important milestone in the continued development of KG Legal&#8217;s Data, AI &#38; Cybersecurity Desk. It has been a great honour to serve as the exclusive expert contributors for Poland to the OneTrust DataGuidance Privacy Overview – Poland, one of the world&#8217;s leading professional legal [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>We are delighted to share an important milestone in the continued development of <strong>KG Legal&#8217;s Data, AI &amp; Cybersecurity Desk</strong>.</p>



<figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="1000" height="1000" src="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png" alt="" class="wp-image-8823" srcset="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png 1000w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-300x300.png 300w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-150x150.png 150w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-768x768.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure>



<p>It has been a great honour to serve as the <strong>exclusive expert contributors for Poland</strong> to the <strong>OneTrust DataGuidance Privacy Overview – Poland</strong>, one of the world&#8217;s leading professional legal compliance resources relied upon by in-house counsel, privacy professionals, compliance officers, multinational organisations and technology companies operating across multiple jurisdictions.</p>



<span id="more-8822"></span>



<p>Preparing this contribution was a long-term project that required several months of intensive legal analysis, research and editorial work. Our objective was not simply to describe the application of the GDPR in Poland. Instead, we sought to create a practical and comprehensive guide reflecting the significant transformation of the Polish regulatory landscape that has taken place in recent years as a result of new European legislation and its implementation into Polish law.</p>



<p>The publication therefore extends far beyond a traditional overview of Polish data protection law. It examines the interaction between privacy, digital regulation, cybersecurity and artificial intelligence, providing readers with practical guidance on the most important legal developments affecting organisations operating in Poland.</p>



<p>Our contribution discusses, among other things:</p>



<ul class="wp-block-list">
<li>the practical application of the GDPR within the Polish legal system;</li>



<li>the powers and regulatory practice of the Polish supervisory authority for personal data protection;</li>



<li>employee monitoring and workplace privacy;</li>



<li>cookies, consent mechanisms and online tracking technologies;</li>



<li>electronic communications and direct marketing requirements;</li>



<li>international data transfers;</li>



<li>personal data breaches and notification obligations;</li>



<li>practical compliance with Polish privacy legislation;</li>



<li>cybersecurity-related regulatory developments;</li>



<li>the growing interaction between data protection and artificial intelligence governance.</li>
</ul>



<p>A particularly important aspect of this work was addressing the rapidly evolving legislative environment. During the last few years, Poland has experienced substantial regulatory changes resulting from the implementation of numerous European legal instruments and the entry into force of directly applicable EU regulations that significantly affect organisations processing personal data.</p>



<p>Accordingly, the publication takes into account the practical implications of the evolving European digital regulatory framework, including the interaction between the GDPR and newer legal instruments governing digital services, artificial intelligence, cybersecurity and data governance. The analysis also reflects the impact of the AI regulatory framework, developments concerning data governance and electronic communications, as well as the increasingly interconnected compliance obligations facing businesses operating in today&#8217;s digital economy.</p>



<p>Rather than presenting legislation in isolation, the publication adopts a practical, compliance-oriented perspective. It combines:</p>



<ul class="wp-block-list">
<li>the GDPR and Polish implementing legislation;</li>



<li>guidance issued by the European Data Protection Board (EDPB);</li>



<li>the jurisprudence of the Court of Justice of the European Union;</li>



<li>decisions and regulatory guidance published by the Polish Personal Data Protection Office (UODO);</li>



<li>recent Polish legislative developments and market practice.</li>
</ul>



<p>Our ambition was to create a resource that would assist both international and domestic organisations in navigating one of the fastest-changing areas of European regulation, where privacy law increasingly intersects with cybersecurity, AI governance, digital platforms, online communications and emerging technologies.</p>



<p>The contribution was prepared by <strong>Małgorzata Kiełtyka</strong> and <strong>Jakub Gładkowski</strong>, whose combined experience covers complex cross-border advisory work in data protection, artificial intelligence, life sciences, healthcare, technology law, cybersecurity, intellectual property and regulatory compliance.</p>



<p><a href="https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski" target="_blank" rel="noreferrer noopener">https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski</a></p>



<p><a href="https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka">https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka</a></p>



<p>For many years, Małgorzata Kiełtyka has advised international companies on GDPR compliance, healthcare regulation, AI governance, technology transactions and cross-border regulatory matters. Her practice combines strategic legal advice with practical implementation of compliance frameworks for multinational businesses operating in highly regulated sectors.</p>



<p>Jakub Gładkowski focuses on data protection, digital regulation, cybersecurity, intellectual property, IT law and emerging technologies. His practice includes advising innovative businesses on regulatory compliance, digital transformation projects and the implementation of European technology legislation affecting both public and private sector organisations.</p>



<p>Being entrusted with preparing Poland&#8217;s national contribution to OneTrust DataGuidance represents an important recognition of our team&#8217;s expertise and international standing. We are particularly proud that this publication reflects not only our experience in privacy law, but also our broader interdisciplinary approach, integrating data protection with AI regulation, cybersecurity, digital compliance and technology law.</p>



<p>We sincerely thank the editorial team at <strong>OneTrust DataGuidance</strong> for their confidence in our expertise and for the opportunity to contribute to a publication that supports legal and compliance professionals around the world.</p>



<p>For KG Legal, this publication marks another significant milestone in the continued growth of our <strong>Data, AI &amp; Cybersecurity Desk</strong> and reinforces our commitment to delivering practical, business-oriented legal advice at the intersection of privacy, technology and innovation.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 18:09:37 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Administrative Law]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Compliance Risk]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[EU Food Regulation]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[GIS Poland]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[International Law Firms]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[Legal Services Poland]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Life Sciences Regulation]]></category>
		<category><![CDATA[Marketing Compliance]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Sanitary Regulation]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8807</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, and supervised in Poland. While the reform does not formally introduce a pre-market authorization system, it undeniably strengthens the position of regulatory authorities and increases the compliance burden imposed on businesses operating in the sector.</p>



<span id="more-8807"></span>



<p id="ember2883">The amendment, expected to enter into force six months after publication, reflects both domestic concerns regarding the rapid expansion of the supplements market and the broader European trend toward stricter food safety oversight. For manufacturers, importers, distributors, and marketing agencies, the proposed changes may require a complete reassessment of internal procedures, legal risk management, and commercial strategy.</p>



<p id="ember2884">The reform arrives at a time when the Polish dietary supplements market continues to expand at an exceptional pace. Poland has become one of the largest supplement consumers in the European Union, both in terms of total market value and per capita spending. According to market estimates, the sector exceeded PLN 7 billion in value in 2024 and is expected to continue growing steadily over the coming years. The scale of the market alone has become a challenge for regulators. Between 2017 and 2020, more than 62,000 supplement notifications were submitted to the Chief Sanitary Inspectorate (GIS), while the number of products listed in official registers exceeded 29,000.</p>



<p id="ember2885">At the same time, authorities increasingly pointed to systemic weaknesses in the existing framework. Under the current rules, a business may place a dietary supplement on the market immediately after submitting a notification to GIS, even if doubts exist regarding the product’s composition or classification. The authorities may initiate explanatory proceedings, but the product can still remain commercially available during the investigation. In practice, this system has often been criticized for providing insufficient preventive control and allowing potentially problematic products to circulate before any meaningful assessment takes place.</p>



<p id="ember2886">Another major concern involved the widespread use of aggressive advertising strategies. For years, the dietary supplements industry has been accused of blurring the line between supplements and medicinal products. Many advertisements indirectly suggested therapeutic effects or implied that supplements could substitute proper medical treatment or balanced nutrition. Regulators and pharmaceutical companies repeatedly argued that existing penalties were too low to deter large market participants from engaging in questionable promotional practices.</p>



<p id="ember2887">The lack of a centralized digital supervision system also contributed to inefficiencies. The notification process relied partly on outdated administrative mechanisms, resulting in difficulties with document verification, inconsistent communication, and lengthy proceedings. The new amendment seeks to address these concerns through digitalization, stricter procedural obligations, and substantially higher financial sanctions.</p>



<p id="ember2888">One of the most visible changes introduced by the reform is the mandatory use of the e-Sanepid platform for all supplement notifications. Until now, notifications could be submitted either electronically or in paper form, and businesses had some flexibility regarding the form and timing of submission. Under the new rules, however, the process becomes fully digitized. Notifications will only be accepted through the e-Sanepid system and will require either a qualified electronic signature or a trusted electronic profile.</p>



<p id="ember2889">This change may appear largely technical at first glance, but in reality it significantly increases the formalization of the entire notification process. For large companies with developed compliance departments, adapting to electronic communication systems is unlikely to create serious difficulties. Smaller businesses, however, may face operational and financial challenges connected with digital authentication tools, procedural monitoring, and document management requirements.</p>



<p id="ember2890">The amendment also changes the moment at which the notification obligation arises. Previously, the law referred both to products already introduced to the market and those merely intended for future introduction. The new wording removes the reference to “intended introduction,” meaning that the obligation will arise only once the product is actually being placed on the market. Although this clarification simplifies the legal interpretation of the obligation, it also narrows the flexibility businesses previously enjoyed when planning product launches.</p>



<p id="ember2891">Perhaps the most consequential aspect of the reform concerns explanatory proceedings and scientific opinions. Under the current framework, businesses could effectively delay proceedings indefinitely by postponing the submission of required scientific documentation. While the law imposed certain deadlines on the authorities themselves, it did not establish sufficiently strict obligations for the notifying entity. This created situations where proceedings remained unresolved for years, significantly limiting the effectiveness of supervision.</p>



<p id="ember2892">The amendment introduces a much stricter procedural regime. Once GIS requests a scientific opinion regarding a product’s classification or compliance, the business will have only 14 days to submit an application to a scientific institution or to the President of the Office for Registration of Medicinal Products. Furthermore, the scientific opinion itself must generally be issued within six months, with an absolute maximum period of twelve months in exceptional cases.</p>



<p id="ember2893">The most significant innovation is the introduction of a legal presumption against the entrepreneur. If the entity fails to submit the application for an opinion within the required 14-day period, the law will automatically presume that the proposed classification of the product is incorrect and that the product does not meet the requirements applicable to its category. In practical terms, procedural inactivity itself may lead to negative legal consequences.</p>



<p id="ember2894">This fundamentally changes the balance between businesses and regulatory authorities. Previously, delaying the process often worked in favor of companies by allowing products to remain on the market while proceedings continued. Under the new rules, inaction may immediately weaken the entrepreneur’s legal position. Businesses will therefore need to implement much stricter internal monitoring systems to ensure compliance with procedural deadlines.</p>



<p id="ember2895">The amendment additionally prohibits businesses from circumventing the procedure by repeatedly submitting notifications for identical products. Once proceedings are initiated, companies will no longer be able to submit another notification concerning a product with the same qualitative and quantitative composition. Similarly, withdrawing a notification will not allow the entrepreneur to restart the process with the same formula at a later stage. These restrictions are intended to eliminate procedural abuse and prevent companies from avoiding regulatory scrutiny through repeated filings.</p>



<p id="ember2896">Another major reform concerns transparency and the expansion of the public product register maintained within the SEPIS system. The current register already contains certain information regarding notified products, but the scope of publicly available data remains relatively limited. The new system significantly broadens the amount of information accessible to consumers and competitors alike.</p>



<p id="ember2897">Under the amendment, the register will include the product name, form of the product, qualitative composition, information regarding active substances, details concerning explanatory proceedings, and information about prohibited ingredients. Although quantitative composition data and certain identifying information regarding the reporting entity will remain confidential, the reform nevertheless represents a substantial increase in market transparency.</p>



<p id="ember2898">From the consumer protection perspective, this may be viewed as a positive development. Consumers will gain easier access to information about supplement composition and regulatory status, potentially allowing for more informed purchasing decisions. However, from the business perspective, the new transparency rules create considerable reputational risks. Information regarding ongoing explanatory proceedings may become publicly visible long before any final administrative decision is issued. As a result, companies may face reputational damage even in situations where no violation is ultimately confirmed.</p>



<p id="ember2899">The reform also updates the broader inspection framework to align Polish law with Regulation (EU) 2017/625 on official controls. Although the regulation has already been directly applicable across the European Union since 2019, several references in Polish legislation still pointed to repealed EU acts. The amendment therefore modernizes the legal terminology and adapts national provisions to the currently binding European framework.</p>



<p id="ember2900">Importantly, however, the changes do not significantly expand the substantive powers of sanitary authorities. The amendment primarily introduces terminological adjustments, extending references from “official food controls” to “official controls and other official activities.” Sanitary authorities will continue to possess extensive powers during inspections, including access to facilities, examination of production processes and documentation, and collection of samples for laboratory testing.</p>



<p id="ember2901">The reform does, however, expand the situations in which businesses must bear the costs of inspections and administrative activities. In addition to existing obligations related to violations, follow-up inspections, and border sanitary controls, businesses will now also be required to cover costs associated with official activities performed at their own request, such as the issuance of certain documents. While this change may appear relatively modest compared to other parts of the reform, it nevertheless contributes to the overall increase in operational costs for market participants.</p>



<p id="ember2902">One of the most controversial elements of the amendment concerns advertising and marketing practices. The reform significantly broadens the scope of administrative liability related to the promotion and presentation of dietary supplements. Previously, penalties focused primarily on incorrect product labeling. Under the new rules, liability will explicitly extend to advertising, online promotion, social media activities, and the overall presentation of products.</p>



<p id="ember2903">Most importantly, the amendment introduces severe sanctions for advertising or presenting a supplement before notifying GIS. This is likely to have a major impact on digital marketing strategies commonly used in the supplements industry. Influencer campaigns, online pre-launch promotions, teaser advertisements, and social media product announcements may all potentially fall within the scope of the new sanctions if conducted before formal notification.</p>



<p id="ember2904">The amendment also reinforces existing prohibitions against suggesting that a balanced diet cannot provide sufficient nutrients or implying medicinal properties of supplements. Although these prohibitions already existed under current law, the reform significantly strengthens enforcement mechanisms by attaching much higher financial penalties to violations.</p>



<p id="ember2905">Indeed, the increase in administrative penalties represents one of the most dramatic aspects of the reform. Under the current framework, the maximum administrative fine generally amounts to thirty times the average monthly salary. The amendment raises this threshold to one hundred times the average salary, increasing potential penalties by more than 330 percent.</p>



<p id="ember2906">Based on current economic indicators, maximum fines could exceed PLN 800,000. Such amounts are clearly intended to function as genuinely deterrent sanctions rather than symbolic administrative measures. For large corporations with extensive marketing operations, these penalties may significantly alter risk calculations related to aggressive advertising or borderline compliance practices.</p>



<p id="ember2907">For businesses operating in the supplements sector, the cumulative impact of these changes may be substantial. Compliance costs are likely to increase considerably. Companies may need to invest in legal advisory services, digital infrastructure, scientific assessments, employee training, and enhanced compliance monitoring systems. Marketing departments in particular will face increased scrutiny and will need to carefully verify advertising content before publication.</p>



<p id="ember2908">The reform may also contribute to market consolidation. Large, well-established companies are generally better positioned to absorb increased compliance costs and adapt to stricter regulatory requirements. Smaller businesses, startups, and niche supplement brands may struggle with the financial and administrative burden created by the new framework. As a result, the amendment could unintentionally reduce market diversity and strengthen the competitive position of major industry players.</p>



<p id="ember2909">From the perspective of public authorities, the reform aims to improve the efficiency and credibility of food safety supervision. Digitalization through e-Sanepid and SEPIS is expected to accelerate administrative processes, improve data analysis capabilities, and strengthen market oversight. The introduction of strict procedural deadlines should also reduce the risk of excessively lengthy proceedings and administrative disputes.</p>



<p id="ember2910">At the same time, the implementation of these systems will require significant investments in technological infrastructure and administrative capacity. The effectiveness of the reform will therefore depend not only on the wording of the legislation itself, but also on the practical ability of GIS and related institutions to manage the new digital environment efficiently.</p>



<p id="ember2911">Ultimately, the amendment does not formally transform dietary supplements into products requiring prior authorization before market entry. Businesses will still be able to introduce supplements through a notification-based system rather than a licensing procedure. Nevertheless, the practical reality of operating in the sector is likely to change considerably.</p>



<p id="ember2912">The reform substantially increases the procedural obligations imposed on businesses, strengthens enforcement tools available to authorities, raises financial exposure connected with non-compliance, and introduces far greater transparency into the market. While these changes may improve consumer protection and market oversight, they also create new operational and reputational risks for entrepreneurs.</p>



<p id="ember2913">For companies active in the supplements industry, the coming months may therefore become a critical period of preparation. Businesses that fail to adapt quickly to the new regulatory environment may face not only financial penalties, but also significant disruptions to their commercial operations and marketing strategies.</p>
<p> </p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
